roche annual report business report innovate healthcareroche business report survey annual report inform roche financial operating result company strategic direction long term value opinion reader ofour reportswe want find reader think annual reportin particular business report click link fill online questionnaire allthis minute opinion help improve business report year ll find questionnaire httpwwwrochebusinessreportsurveycom thank support difference complete questionnaire receivedroche donate swiss franc reactan independent foundation pool roche employeesinitiative skill support select charitable project organisation company designate survey response donation react support phelophepaa mobile health train serve rural village south africaphelophepa see av erage ofover patient year previously access basic health care complete questionnaire help provide funding expertise sustainable work south africainnovation span entire healthcare spectrum pharmaceutical diagnostic company roche bring pioneer product service market stage healthcare process identify disease susceptibility testing disease atrisk population prevention diagnosis therapy treatment monitor focus product deliver significant benefit patient health professional core element business strategy key reason success researchintensive company longterm strategic focus roche strive deliver sustainable value stakeholderspredisposition table content information predisposition todisease offer huge potential business report butweve get long way key figure year brief letter chairman roche group early detection group result outlook ifi not determine group strategy tofind heri notbe alive today tell story pharmaceutical pharmaceutical division brief result therapeutic area research development prevention rd pipeline little brother catch flu diagnostic get holiday diagnostic division brief result business area research development key product launch schedule diagnosis corporate governance remuneration report ifmy doctor not think ofit corporate governance d know hep c remuneration report create sustainable value management approach key management topic therapy people ve get life child get community father safety health environmental protection assurance monitor gri statement roche global market presence monitor blood glucose day hospital month business report key figure roche group index sale mchf equity ratio research development mchf total employee remuneration mchf operating profit exceptional item mchf dividend mchf income taxis mchf number employee profit continue business mchf patient participate clinical trial core earning share chf ecoefficiency rate index index price development nonvoting equity security genussschein chf roche nonvoting equity security swiss market index rebase continue business figure annual report key figure index index global reporting initiative gri indicator propose board director report wwwrochecomsusgri development phase iv calculation ecoefficiency rate wwwrochecomsussheperformance business report year brief group group sale advance billion swiss franc record increase billion swiss franc operating profit margin increase percentage point net income billion swiss franc drive strong operating performance significantly high net financial income board propose th consecutive dividend increase swiss franc share nonvoting equity security pharmaceutical pharmaceutical sale grow time fast global market division reinforce leadership oncology operate profit margin rise percentage point marketing approval receive avastin lung cancer herceptin early stage breast cancer mabtherarituxan rheumatoid arthritis marketing application file mircera renal anemia major development target meet new marketing application file approval receive diagnostic division post sale growth consolidate global market leadership anticipate divisional operating profit decline result investment new product launch impairment charge intangible asset low royalty income licence molecular diagnostic segment new range accuchek blood glucose monitoring product available worldwide outlook doubledigit sale growth roche group pharmaceutical division abovemarket sale growth division core earning share growth target line sale growth additional information roche visit httpwwwrochecom growth rate base local currency operate profit operate profit margin state exceptional item business report business report letter chairman year strong growth exceptional item increase local cur outstanding financial performance roche rencie billion swiss franc group group sale rise local currency record operating profit margin increase furtherto high billion swiss francsthis billion swiss timewe invest division franc revenue increase reflect organic rich research development pipeline growth topline growth drive primarily increase spending launch activity con pharmaceutical divisionwhere sale advanced struction ofnew biotech manufacturing facility time market growth rate roche diagnostic maintain leadership net financial income significantly position increasingly competitive market compare total net income rise thank numerous new product launch billion swiss franc high profit continue growth division business record roche core earning share area core ep rise group earning performance improve sig board director propose divi nificantly year operating profit dend increase swiss business report letter chairman franc share nonvoting equity security roche strategy remain firmly focused pre swiss franc subject scription medicine modern diagnosticswith approval annual general meeting share increase financial strength holdersthis th consecutive dividend resource target businessbuilde invest increase ment ofthese core businessesdevelope healthcare innovation product services rep indicate beforethe pharmaceutical division resent real advance fight main driver group excellent disease important thing roche result sale exceed billion swiss mission change franc increase local currency research development activity aim market average growth year extend patientslive improve health robust increase drive primarily sus quality oflifeworldwidewe spend million taine strong demand cancer medicine swiss franc day pursuit oftheseobjective continue government stockpile anti year rd expenditure pharmaceuticals influenza drug tamiflu sale ofbonvivaboniva division amount sale absolute osteoporosis oncology transplantation figurestotal rd expenditure group rise virology currently lead therapeutic billion swiss franc make franchise importantly sale cancer roche researchintensive compa medicine surge approximately billion ny industry swiss francsand account half divi sion total revenuesfor timethe pharma plan intensify cooperation ceutical division operating profit excep pharmaceutical diagnostic division tional item exceed billion swiss francsand major therapeutic area order deliver operate profit margin rise significantlyto product tailor need specific patient population benefit precise diag diagnostic division post sale billion nose well target treatment swiss francsa increase local currency evident particularly oncology tight cross previous year slow start sale growth divisional linkage researchdevelop accelerate slightly market growth rate ment marketing organisation strengthen second half year help roll ability actively shape future oftherapeu new product division tic diagnostic centralized diagnostic business particularly immunodiagnostic portfolio main con roche reselecte inclusion dow tributor growth new portfolio jones sustainability indexes ftsegood accuchek blood glucose monitoring product index series recognition effort marketwe expect roche diabete care balance corporate responsibility business return abovemarket growth divi objective core mission innovate healthcare sional operating profit exceptional item believe make sustainability integral decline local currency approximately business model operation foster billion swiss francsthe decrease primarily innovation minimise business risk create high cost new product launch value stakeholder ongoing pricing pressure division market operating profit impact impairment final analysisof courseit roche people charge intangible asset relate dise prosperousinnovative com tronic acquisition pany todaythank untire dedication business report letter chairman professionalism roche able bring prod uct service market real differ ence patientslive strong business con tinued create new job yearin total number roche employee worldwide increase like additional opportunity thank roche group employee tremendous job continue tough challenge marketplacethe award receive year outstanding com pany work special source ofpride ofus roche innovation medical progress access quality healthcare unsustainable reasonit vital raise awareness role pricing patent protection play industry ability innovateroche continue actively engage policymaker public issue tomorrow healthcare market offer enormous opportunity pose enormous challenge roche pursue opportunity tackle challenge confidence position strengthwith strategy focus innovation portfolio new productswe equip sustained growthin expect group pharmaceu tical division sale grow doubledigit rate local currenciesand expect continue abovemarket sale growth division aim core eps increase line group sale franz bhumer business report information predisposition disease offer huge potential ve get long way business report predisposition testing hold promise predictive preventative medicine identify individual risk complex disease isstill challengewhile technology genetic testing pcr microarray available identify right prognostic marker straightforward taskhenry erlichvp research director human genetic roche molecular diagnostic leftin main pictureis good position knowas internationally recognise expert genetic factor associate disease contact theglobal research community estimate risk disease standard clinical practicesuch measure blood pressure cholesterol risk factor stroke heart attackgenetic predisposition test canbecome clinical practicesay erlich buta number challenge meet firstand need aglobalinterdisciplinary effort researcher world begin address challengesaccorde erlich predisposition testing couldaid design clinical trial understand natural course diseaseinmany casesthe genetic marker oneday alsohelp clinician select besttherapythey point way new discovery allow doctor prevent disease occur predisposed individual predisposition predisposition marker predictive disease effective preventive measure available exam ple statin blood pressure medication routinely pre scribe reduce risk cardiovascular disease individual elevate risk similarly osteoporosis medicine pre scribe predisposed individual lose signifi not bone mass preventive measure reduce public health burden disease expand market effective medicine business report roche group group result division operate profit margin decline percentage point mar operationally financially gin decrease primarily investment outstanding year roche group total sale rollout ofnew productsimpairment charge increase significantlyrise local curren intangible asset low royalty income cie swiss franc billion swiss licence franc billion swiss franc increase revenue organic growthsale contin group strong profitability reflect ued grow especially strongly pharmaceuti key indicator ebitda rise billion cal divisionit sale increase year swiss franc billion swiss franc local currency swiss francsor time global market growth rate lead net financial income total million swiss strong demand cancer medicine herceptin francsup significantly million swiss avastin mabtherarituxanthe antiinfluenza franc record effective tax rate medicine tamifluand bonvivabonivafor osteo compare porosisas resultroche extend market lead ership oncologytransplantation virologyin group net income rise billion swiss diagnostic division sale increase local francsto billion swiss francsand group currency swiss franc billion swiss return sale margin increase percentage francswith centralized diagnostic unit mak point net income attributable roche ing large contribution growthdiagnostic shareholder high year sale accelerate grow slightly core earning share core eps rise ahead ofthe market year group balance sheet strengthen ratio equity total asset robust increase group sale year ofasset finance longterm positive impact earning perform ance group operating profit excep tional item increase local currency outlook billion swiss francsthe correspond oper ate profit margin rise percentage point bar unforeseen event roche anticipate fur sale growth offset ther positive growth expect group increase investment roche strong develop pharmaceutical division sale con ment pipeline new product launch tinue togrow doubledigit rate local curren ciesinboth pharmaceutical division group improve earning performance diagnostic divisionroche anticipate continue primarily significantly high profit con abovemarket sale growth local currency tribute pharmaceutical divisionthe divi roches target core eps grow line sion operating profit exceptional item group sale despite significant investment increase local currency billion researchdevelopmentproduction marketing swiss francsresulte margin improve ment percentage point diagnostic division post operate earning exceptional item financial profit billion swiss francsdown local income financing cost tax depreciation amortisa currency high divisional profit record tion include impairment business report roche group group strategy trend fuel demand highquality healthcare patient empowerment people trend market today well inform health issue medical advance world population grow standably demand greater large old great number people decision affect care affect disease age cancer want access late medical procedure alzheimer disease diabete rheumatoid medicine arthritis example prevalent making urgent find health system financially effective way treat grow stretchedhow demand satisfied age populationpeople go need healthcare keep affordable well healthcarenot ofthe pioneer personalise medicine healthcare thing size fit gene countless environman tal factor influence outcome treat ment receive include response medicine disease occur genetically distinct subtype vary clinical course prognosis patient seemingly disease treat medicine respond radically different way benefit treatment experi ence unwanted effect clinical benefit fight hivaid hepatitis c doctor routinely perform viral load test guide treat roche commit provide healthcare pro ment selection track patient response treatment fessional powerful diagnostic tool dosing adjustment necessary target treatment base science increase understanding disease arise molecular test play key role development level approach promise steady new antiviral drug similar success achieve improvement therapeutic option available oncology rheumatology say dr tim jaeger patient innovative diagnostic technology picture head drive personalise health physician increasingly able identify patient care initiative roche diagnostic pharma population likely benefit particular ceutical division work example treatment well way detect differentiate certain cancer exploit new mechanism drug recent year roche provide example action provide specific group patient link diagnostic pharmaceutical knowledge effective target treatment project like lead personalise healthcare roche pioneer improve patient care ultimately great deal toease pressure stretch healthcare budget business report roche group group innovation network majority shareholding alliance license agreement spinoff medical progress essential provide sustain prioritise area significant unmet need able access highquality care point expertise difference area government payer agree stay like oncology virology diabete inflammatory competitive today increasingly costsensitive andmetabolic disorder disease ofthe central marketresearchbase healthcare company like nervous system aim leader roche need develop product health eco area interest today roche nomic clinical benefit medicine market leader highgrowth therapeutic area extend patient life improve quality life oncology transplantation hepatitis few effect offer bothand world leader molecular centralized diagnostic test reduce treatment cost diagnostic diabete management help physician choose appropriate therapy patient time worldclass rd backbone strategy diagnostic account healthcare spend billion swiss franc spendingyet timelyaccurate diagnostic informa come year tion require roughly clinical continue increase rd budget select decision area opportunityour innovation model rely cuttingedge drug diagnostic clinically differentiate product create value research global collaborative rd network stakeholder roche majority shareholder genentech united states chugai japan roche prime strategic focus innova company operate largely independently tion strive develop clinically differentiate believe encourage great diversity solution medical need approach increase chance success adequately address create value additionthe group research capability stakeholdersfrom patientsto providersto health augmented host scientific commercial care system wholewe devote resource collaboration external biotech company researchintensive businessespharmaceuti university research organisation cal diagnostic business world business report roche group recognise innovation require perseverence longterm perspectivewe invest early new technology judge critical longterm viability strength develop ment pipelineroche pharma ceutical company enter biotech arena establish relationship genentech early majority share holder time molecular research infancy time acquire worldwide right polymerase chain reaction pcr technological advance molecular biology develop diagnostic product continue set new stan dards speed accuracy today biopharma ceutical account half group salesand roche global market leader molecular diagnostic biotechnology open completely new approach diagnose treat diseasepar ticularly cancer development portfolio cur rently include therapeutic protein develop total indication invest heavily new manufacturing facility meet grow demand bio therapeutic biodiagnostic emerge field personalise medicine tremendous potential healthcare well safe costeffectivewith combine strength diagnostic therapeutic equip lead realise potential pioneer personalise medicinep pharmaceutical research network strength biotechnology leadership diagnostic rd competitive advantage ina change marketplace believe deliver great value innovation strategy sell metoo product generic overthecounter remedy economic clinical benefitstargete therapy diagnostic test support well medical decisionmaking likely approve regulator accept patient cover reimburse payersour goal deliver innovation benefit health care stakeholdersand s change business report not determine find alive today tell story business report find cancer type help patient right treatment donna rullofrom northw victoria australiawas treat early breast cancer insomething doctor say stand yourcancer herpositivedonna immediately start gather information determine find mean outlook treatment option donna learn herpositive tumour particularly aggressivegrow fast likelyto relapseher search information ledherto richard bellhead cancer care geelong hospitalhe enrol donna clinical trial investigate effectiveness herceptin trastuzumab early herpositive breast cancerherceptin specifically design treat herpositive tumour breast cancer not single diseaseit stage type factor influence treatment decision expect outcomesexplain profbell thecancer detect early treatment tailor thespecific tumour patient characteristic well outcome achievedi not stress important determine aspect type breast cancer early possible optimise treatment planning donna case early identification breast cancer herpositive target treatment herceptin pay stay remission early detection important early diagnosis breast cancer fast iden tification tumour type help doctor estimate quickly cancer grow respond spe cific treatment example know breast cancer patient status diagnosis enable doctor select effective treatment programme increase patient chance survival business report pharmaceutical division brief sale million chf operating profit exceptional item millions chf publish annual report number employee key figure change change millions chf chf local currency sale sale roche pharmaceutical genentech chugai ebitda operate profit research development exceptional item pharma executive committee january william burns ceo division roche pharmaceutical george b abercrombie north america jennifer allerton informatics jeanjacques garaud development eduard holdener chief medical officer peter hug partner jonathan kc knowles research dominic p moorhead finance control paul newtonsyms human resources claude schreiner western europe pascal soriot commercial operation jan van koeveringe technical operation business report pharmaceutical division sale region roche group pharmaceutical division ofroche pharmaceuticalsrepresente latin america countriesand majority shareholding japan genentech united states chugai japan roche cooperate closely genentech chugai maintain license collaborative agreement company europe world give roche group wide north america access promise experimental medicine cuttingedge technology italic growth rate result strong sale growth combine pro ductivity improvement particularly manu pharmaceutical division set new record facture factor outweigh sale year rise local cur significantly high investment marketing rencie swiss franc dollar distribution research development billion swiss franc billion franc ebitda total billion franc time global market salescompare growth rate roche outperform global pharmaceutical market quarter year regional sale growth sig therapeutic area nificantly outpace market average north america vs europe vs oncology japan sale decline line market average governmentmandate price cut roche group world lead provider healthcare reimbursement change cancer medicine mabtherarituxan herceptinavastinxeloda tarcevathe group overall growth drive primarily strong currently market innovative cancer treatment demand division key oncology product show significantly extend patient influenza medicine tamiflu genentechs survivalwe continue investigate new use ophthalmology drug lucentisand osteoporosis effective combination group medicine bonvivaboniva anticancer product extensive development programme major development activitiesp division operate profit exceptional item advance billion swiss franc operating margin percentage point state growth rate local cur tothe margin increase result ofthe rencie business report pharmaceutical sale therapeutic area know herpositive account breast cancer worldwide sale theproduct nearly double addition strong uptake medical community growth respiratory disease drive mainly reimbursement approval metabolic disease euthe key market wide use bone disease product surgery earlystage breast central nervous system cancer approval base clinical trial infectious disease result show set herceptin cardiovascular disease reduce risk cancer recurrence inflammatory risk death thirdin october autoimmune disease roche file application eu authority transplantation approval ofherceptin combine hormonal virology therapy treat advanced metastatic breast cancer ophthalmology na hormone receptorpositive positivein november chugai file application renal anemia japanese ministry healthlabour oncology welfare mhlw seek expansion pro italic growth rate duct marketing licence include operable early stage herpositive breast cancer sale roche group oncology portfolio grow account information roche clinical trial visit roche pharmaceutical sale clinical trial registry wwwrochetrialscom roche clinical trial protocol registry trial result sale mabtherarituxan rituximab database p report treatment indolent aggressive form nonhodgkin lymphoma nhl continue avastin bevacizumab target anti advance strongly growth angiogenic therapy demonstrate patient support increase use product survival benefit major tumour type firstline treatment form disease metastatic colorectal breast lung cancer particularly europe emerge market advance kidney cancer avastin russia latin americahigh treatment rate inhibit growth blood vessel tumour rituxan maintain cut blood supply tumour need yearin july roche receive eu regulatory grow spread launch approval market mabthera maintenance market worldwide firstline treatment therapy relapse refractory follicular nhl advanced metastatic colorectal cancer crc common form indolent nhl sale grew strongly expect genentech receive marketing approval increase drive continue market additional indication rituxaninclude uptakeroche prepare ask eu authority treatment previously untreated follicular lym widen product current marketing approval phoma metastatic crc include combination chemotherapy regimen base xeloda oxali herceptin trastuzumab design specifically platin filing plan half treat particularly aggressive form tumour base datum largestever clinical trial firstline metastatic crc show add avastin chemotherapy folfox xelox significantly improve progressionfree oncology portfolio mabtherarituxan herceptin avastin xeloda tarceva bondronat kytril furtulon neupogen survival compare chemotherapy neorecormon roferona neutrogin picibanil april chugai file marketing application vesanoid avastin japanfor treatment ofadvance business report pharmaceutical cancer disease world lead provider cancer estimate million new case annually lung medicine roche group work hard cancer common form cancer worldwide help meet enormous need new treatment leading cause cancer death world andin option target therapy europe nonsmall cell lung cancer isthe common form lung cancer account approximately cancer abnormal growth cell proliferate case tarceva avastin uncontrolle cell division malignant cell invade tissue spread metasta year people worldwide diag sise distant part body cancer nosed kidney cancer die disease group distinct disease rate expect increase kidney disorder main cause death cancer common man incidence industrialise country increase age renal cell carcinoma account kidney cancer avastin roferona nonhodgkin lymphoma group cancer affect lymphatic system grow inci pancreatic cancer particularly aggressive disease dence early class extremely difficult treat resistant cancercurrently affect million people world chemotherapy radiotherapy tend spread wide mabtherarituxan quickly part body kill high pro portion patient year diagnosis colorectal cancer cancer large intestine cancer fifth leading cause cancer rectum account million new case death develop world pancreatic cancer newly diagnose cancer worldwide claim live people year tarceva year second common cause cancer xeloda deaths europe main treatment surgery combine radiotherapy stomach cancer account close million new chemotherapy avastin xeloda case death year make second common type cancer breast cancer common cancer secondlarg cause cancer death worldwide woman worldwide million woman newly main type cancer see china korea diagnose die disease japan case occur xeloda year different type breast cancer knowledge tumour characteristic important information visit treatment decision herceptin xeloda avastin httpwwwrochecomdiseaseshtm recurrent colorectal cancerthe application filing indication submit file early mhlw initiative aim eus european medicines agency emea expedite patient access innovative medicine august addition roche file application approve usor euand july eu marketing authorisation avastin give priority review status treatment advanced breast cancer september fda ask genentech provide octoberfollowe priority reviewthe food additional datum analysis support applica drug administration fda approve avastin tion approval avastin treat metastatic treatment nonsmall cell lung cancer breast cancergenentech agree supply nsclc common form disease additional datum mid business report pharmaceutical topselle pharmaceutical product roche group sale change product generic indication millions chf local currency mabtherarituxan rituximab nonhodgkin lymphoma rheumatoid arthritis herceptin trastuzumab metastatic breast cancer adjuvant breast cancer avastin bevacizumab metastatic colorectal cancer advanced nonsmall cell lung cancer tamiflu oseltamivir treatment prevention influenza b neorecormon epogin epoetin beta anemia cellcept mycophenolate mofetil transplantation pegasys peginterferon alfaa hepatitis b c xeloda capecitabine colorectal cancer breast cancer tarceva erlotinib nonsmall cell lung cancer advance pancreatic cancer xenical orlistat weight loss weight control xolair omalizumab asthma kytril granisetron nausea vomit induce chemotherapy radiation therapy follow surgery nutropin somatropin growth hormone deficiency bonvivaboniva ibandronic acid osteoporosis valcyte cymevene valganciclovir ganciclovir cytomegalovirus infection lucentis ranibizumab wet agerelate macular degeneration pulmozyme dornase alfadnase cystic fibrosis rocephin ceftriaxone bacterial infection neutrogin lenograstim neutropenia associate chemotherapy activase tnkase alteplase tenecteplase acute myocardial infarction heart attack jointly market genentech novartis interim analysis major phase iii trial metastatic breast colorectal cancermarkete avoren release december show application plan worldwideexcept japan avastin effective fourth type cancer half approval com significantly improve progressionfree survival bination xeloda oxaliplatin avastin give firstline treatment advance metastatic colorectal cancer filing renal cell carcinoma result form base result phase iii study com basis supplemental eu marketing application plete plan july roche file eu marketing application xeloda capecitabine effective oral anticancer approval xeloda combination therapy greatly simplify treatment cisplatin treatment stomach cancer save cost reduce need hospital visit file base result phase iii strong sale growth fuel mainly comparative study efficacy safety increase use product adjuvant treat combine xeloda cisplatin versus current ment ofcolon cancer europexeloda standard therapy currently approve treatment business report pharmaceutical major product approval product generic indication dosage form country avastin bevacizumab secondline metastatic colorectal cancer usa combination fubase chemotherapy firstline nonsmall cell lung cancer usa bonvivaboniva injection ibandronic acid osteoporosis intravenous formulation usa eu switzerland copegus ribavirin chronic hepatitis c combination pegasys japan epogin epoetin beta anemia premature infant japan femara letrozole breast cancer postmenopausal women japan herceptin trastuzumab adjuvant earlystage herpositive breast cancer usa eu switzerland invirase saquinavir hiv disease mg tablet japan lucentis ranibizumab wet agerelate macular degeneration usa mabtherarituxan rituximab rheumatoid arthritis antitnf failures usa eu switzerland firstline treatment diffuse large bcell cdpositive usa nonhodgkins lymphoma nhl firstline treatment patient follicular nhl usa combination cvp chemotherapy maintenance therapy patient relapse eu refractory follicular nhl switzerland treatment lowgrade nhl follow firstline usa treatment cvp chemotherapy neorecormon epoetin beta onceweekly treatment anemia patient solid eu tumour receive chemotherapy iu prefille syringe tamiflu oseltamivir pediatric influenza prophylaxis eu switzerland tarceva erlotinib metastatic pancreatic cancer combination gemcitabine eu include supplemental indication update january jointly market chugai novartis jointly market genentech novartis year launch sale usage anemia tarceva erlotiniba target drug prove survival benefit advanced nonsmall cell lung anemia occur number ofre blood cell cancer advance pancreatic cancercontinue fall normal starve organ tissue increase strongly tarceva approve oxygenit see ofpatient second thirdline treatment ofnsclc chronic kidney renal disease condition country worldwide april chugai affect million people worldwide file application japan approval oftarceva anemia see cancer patient advance recurrent nsclc filing undergo chemotherapy potential long give priority review status authority term effect anemia include cardiovascular dis market uptake oftarceva treatment ofpan ease renal patientswhile patient cancer creatic cancer strongand product associate reduce survival dimin market leader indicationin ishe quality liferoche support basic research january reexamine datum support anemia funding ofthe independent ing roche supplementary marketing application roche foundation anemia research pro eu authority approve tarceva treat moting advance sciencep ment ofmetastatic pancreatic cancer business report pharmaceutical despite sustained pricing pressure sale neo sale cellcept mycophenolate mofetil con recormon epoetin beta rise billion swiss tinue solid growth drive francswith product retain strong position particularly strong demand thank cancerrelate anemia market leadership prove longterm survival benefit low renal anemia region solda toxicity cellcept remain lead product market share gain oncology set mycophenolic acid market cornerstone drive continued adoption conve ofimmunosuppressant therapy nient onceweekly prefille syringe formulationin january eu authority approve use virology onceweekly dosage form treat anemia patient solid tumoursin japan sale ofepogin combine sale valcyte valganciclovir epoetin beta decline governmentman cymevene ganciclovir continue grow strongly date price cut introduction flatrate drive increase recognition reimbursement epoetin product dialysis doctor need prevent treat cyto patient reduce overall size megalovirus infection transplant patientswhich anemia market combine sale neorecormon fatalsale helped increase epogin decline slightly overall year use ofthe product treat cytomegalovirus infec tion hivaids patient mircerathe continuous erythropoietin recep tor activatoris new antianemia agent differ influenzaor fluis highly contagious viral illness exist medicine functionally occur mainly autumn winter structurallyin april roche file marketing month temperate climate yearround application approval ofmircera treat anemia tropical area particularly dangerous result chronic kidney diseasethe eu young childrenthe elderly people chronic filing seek approval use product health problem year million people patient dialysis fall ill flu europe japan dialysis major development activitiesp aloneinfluenza outbreak occur yearthough december fda accept additional datum extent severity vary widely pandemic submit roche facilitate agencys review orglobal epidemicsoccur year marketing application extend affect halfthe world population review period month trial patent lawsuit bring amgen worldwide sale tamiflu oseltamivir contin expect begin september roche ued rise strongly drive mainly pandemic remain confident mircera infringe stockpilingas government increase popula ofamgen erythropoietin patent tion coverage country place order pandemic stock oftamifluwith transplantation purchase cover oftheir populationsthrough collaborative network ofit number organ transplant perform facilities ofother companiesroche worldwide remain steady approximately access manufacturing capacity annually medical science extend life tamiflu exceed government order receive expectancy patient transplant organ dateresearch effective utilisation demand continue increase safe effective tamiflu hn virus continue immunosuppressant control transplant rejec roche collaboration tion medicine combat infection associ independent expert world health organiza ate transplantation roche support basic tion institutionsfollowe eu approval transplantation research funding tamiflu influenza prophylaxis child independent roche organ transplantation aged year medicine pre research foundation promote advance scribe treatment prophylaxis patient sciencep aged year old business report pharmaceutical balance business responsibility plan pandemic influenza roche antiviral drug tamiflu play key role manage influenza pandemic tamiflu life cycle team work closely world health organization govern ment world plan event lesson learn role indevelope strategy combat hivaids africa hn strain influenza currently circulate bird lead human pandemic mutate intoa form transmit easily person need include lower uniform person government begin establish price government stockpile drug pan national pandemic plan stockpile medicine demic use deep price reduction develop supply tamiflu oseltamivir identify country increase access world critical antiviral demand soar populate country grant sublicence major manufacturer india china pro roche boost production capacity meet vide technical knowhow south african manu surge demand restrict availability facturer expedite production generic version drug treat prevent seasonal flu oseltamivir africa cause thousand death year say pandemic taskforce leader david reddy second right addition roche donate million treatment teammember october take course send immediately epi additional supplier expand global manu centre pandemic outbreak occur facture network include multiple roche site million regional stockpile use contractor country result poor country limit stock drug annual production capacity increase million treatment course end contribution pandemic preparedness time capacity example longstanding commitment working government international agency roche implement balanced pricing patent stakeholder address major public health policy help ensure tamiflu available need hepatitis b c viruse hbv hcv cause million new case occur yearhepatitis c acute chronic liver diseasepotentially lead main reason liver transplantation liver failure cirrhosis liver cancer world wide million people think chron despite overall decline market volume ically infect hbv highly infectious competition combination treatment pathogen responsible estimate mil japan sales pegasys peginterferon alfaa lion death annuallymore million people treatment ofhepatitis b ccontinue world infect hcvand grow product remain lead business report pharmaceutical pegylate interferon treatment chronic hepati indication issue fda emea tis c sale copegus ribavirin continue use patient active ra decline overall generic competition inadequate response unable tolerate january chugai receive approval antitnf therapylaunche useu market copegus japan treatment commence chronic hepatitis c combination pegasys actemra tocilizumab firstinclass humanise prove medicine diagnostic test monoclonal antibody design block inter roche contribute global effort combat leukin important protein involve hiv infection aidswe continue help inflammation associate ra april improve standard hiv care worldwide chugai file marketing application japan initiate support project use actemra treatment adult ra difference local level information systemic onset juvenile idiopathic arthritis initiative roche help expand access support datum include phase iii result show hivaids treatment develop worldsee actemra monotherapy significantly improve play active role p ofthis report visit symptom ra slow progression httpwwwrochecomhomesustainabilityhtm joint damageroche plan file marketing appli cation actemra ra eu roche hiv medicine achieve steady growth product currently approve japan sale fuzeon enfuvirtide treatment castleman disease rare work block entry ofhiv cell lymphatic condition major development immune system rise compare activitiesp combine sale invirase fortovase saquinavir increase million swiss major product franchise francsgrowth fuel increase uptake recently introduce invirase mg tablet osteoporosis cause gradual loss ofbone density offer patient great convenience make bone brittle prone breakit affect million people worldwide especially woman rheumatoid arthritis menopause rheumatoid arthritis ra autoimmune dis bonvivaboniva ibandronic acid order characterise joint inflammationbut oncemonthly oral bisphosphonate approve disease affect lungseyes bone mar treatment postmenopausal osteoporosis roweven treatedit result progressive worldwide rollout gather pace fullyear joint destruction loss mobility exact sale ofthe product continue rise stronglyin cause ofra unknownand cure boniva account ofnew bis year develop raup phosphonate prescriptionsnew datum publish patient xray evidence joint damageand september patient monthly boniva year unable work perform tend continue treatment significantly long everyday task ra common take weekly bisphosphonatesthus increas autoimmune disorder think affect ing chance sustain treatment result million people worldwide current treat bonvivaboniva injection approve ment include diseasemodifye antirheumatic europe january marchrespectivelyand drug dmards biologic medication currently launch marketsgiven inhibit tumour necrosis factor tnf inflam month new formulation matory cytokine offer effective treatment woman unable tolerate oral bisphosphonate mabtherarituxan therapy develop ra selectively target b cell play global sale ofxenical orlistat mgfor weight key role disease approval lossgrew steadily despite launch business report pharmaceutical advance treatment rheumatoid arthritis traditional thinking mechanism cause inflammation tis sue damage observe joint people rheumatoid arthritis ra challenge jonathan edwards professor medicine university college london immune cell call lymphocyte consider key factor drive ra research carry edwards colleague geraldine cambridge suggest type immune cell call b lymphocyte far important ra generally appreciate sente major new opportunity ra lead researcher focus potential role roche scientist begin design fullscale b cell edward convinced target clinical trial e b cell offer way prevent inflam mation deformity ra year clinical experience ritux imab ra clear product effective begin look medicine capable welltolerate treatment option patient active achieve mabtherarituxan ritux disease encourage imab selective bcell depleting monoclonal antibody patient treat prof edwards team show effective treatment time show sign resistant ther typeof cancer call nonhodgkin lymphoma apy mabthera continue successfully control edwards cambridge decide medicine disease number patient rituximab test patient longstande severe godsend say edward patient rawho respond treatment ra severe unable rapidly show major improvement num bed lunchtime ber patient treat soon increase halfway walk day go trial evident mabthera repre work new competitor number market growth research development help increase awareness ofthe risk associate overweight obesityfollowe recent year roche group bring receipt approvable letter fda market effective new treatment different april partner glaxosmithkline discus type cancera medicine represent sion agency application important advance treatment hepatitis sell orlistat mg nonprescription weightloss hiv osteoporosisroche aim expand aid ussubject final fda approvalgsk success major area auto expect launch product brand immune metabolic disease disorder alli halfof central nervous system business report pharmaceutical group phase iii clinical trial meet primary endpoint major trial report positive followup datum product indication trial result actemra rheumatoid arthritis satori significantly improve disease score acr acr compare methotrexate avastin xeloda metastatic colorectal cancer firstline treatment avastin significantly long progressionfree survival compare chemotherapy xeloda effective fluorouracil fu term progressionfree survival combine oxaliplatin avastin renal cell carcinoma avoren significantly long progressionfree survival compare interferon bonvivaboniva osteoporosis mobile followup sustain efficacy hip spine good tolerability year herceptin metastatic breast cancer combination significantly long progressionfree survival anastrozole hormonal treatment tandem time progression compare hormonal treatment herceptin adjuvant breast cancer significantly long overall survival hera month followup reduce risk death compare withchemotherapy herceptin adjuvant breast cancer significantly long overall survival bcirg month followup reduce risk death compare treatment follow completion adjuvant chemotherapy mabtherarituxan indolent nonhodgkin lymphoma significantly long overall survival firstline treatment rcvp followup reduce risk death compare cvp mabtherarituxan rheumatoid arthritis significantly well inhibition structural reflex month followup damage joint compare methotrexate mircera renal anemia correction hemoglobin level effective epoetin dialysis patient amicus darbepoetin term response rate mircera renal anemia correction hemoglobin level effective epoetin predialysis patient arcto darbepoetin term response rate xeloda gastric stomach cancer ml effective fu term progressionfree survival withbetter response rate xeloda esophagogastric cancer real effective fu term overall survival significant overall survival advantage combine oxaliplatin xeloda metastatic colorectal cancer secondline treatment effective fu term progressionfree survival combine oxaliplatin business report pharmaceutical foldout rd pipeline cid research project major therapeutic area roche pharmaceutical currently project january preclinical research therapeutic area development project therapeutic areasincluding phase transition pre oncology clinical clinical development central nervous system project terminate viral disease revert rd partnersof theseeight phase isix phase ii phase iii respiratory disease inflammatory autoimmune engage partnership bone disease cardiovascular roche pharmaceutical continue metabolic disease strengthen rd portfolio enter flex ible licensing collaborative agreement complement group inhouse activitiesdur ing year new agreement signedinclud roche group promising research e product transaction research project latestage development compound technology collaborationsin addition new testimony expertise codevelopment project chugaiannounce research development specialist julyroche sign agreement second half commitment goalcreating bring year plexxikon target cancer com ing market innovative clinically differentiate poundintermune protease inhibitor hepati medicine fifth consecutive year tis c actelion sp immunomodulator roche pharmaceutical name science list autoimmune disorder ofthe employer biotech pharma ceutical industry move place major development activity field ofover companiesgenentecha member ofthe roche groupwas rank number oncology roche partner continue explore roche continues refine rd selection crite benefit avastin tarceva xeloda herceptin ria maximise success project reach mabtherarituxan additional important phase iii clinical testingthe costly time cancer indication combination consume drug development process treatment comprehensive group phase iii clinical trial clinical development programme oncology successfully reach primary clinical end portfolio expand promising point compound progress clinical develop ment rd pipeline mode action avastin demon pharmaceutical division file new strate effectiveness wide range solid marketing application gain regulatory tumoursroche genentech currently test approvalsat beginning division ing avastin distinct type cancer rd pipeline comprise clinical project plan development avastin include new molecular entity nme study phase iii trial adjuvant additional indication twentyfive nme treatment colon cancer advance currently phase phase ii phase metastatic pancreaticprostate ovarian iii file regulatory reviewin total cer test combination number latestage project nmes addi tarceva nsclc combination tional indication increase ceptin drug metastatic breast cancer business report jb eng pipeline uhr seite rd pipeline strengthen therapeutic area project d projectproduct generic pharmacological class indication phase partner cardiovascular r dual ppar agonist type diabete ii metabolic disease r glucokinase activator type diabete ii r type diabetes r type diabete r glp glp analogue type diabetes ii ipsen bim r cetp inhibitor dyslipidemia ii japan tobacco jtt r anticoagulant hematology r mircera continous erythropoietin receptor activator renal anemia file nephrology useu r cera continous erythropoietin receptor activator cancerrelated anemia ii inflammatory autoimmune r mabtherarituxan rituximab anticd monoclonal antibody rheumatoid arthritis dmard inadequate responder iii genentech biogen idec bone disease r valcyte valganciclovir inhibitor cmv replication ulcerative colitis r multiple sclerosis r p kinase inhibitor rheumatoid arthritis ii r actemra tocilizumab humanise antiil receptor monoclonal antibody rheumatoid arthritis iii chugai file jpn r actemra tocilizumab humanise antiil receptor monoclonal antibody systemic onset juvenile idiopathic arthritis iii chugai file jpn r ocrelizumab humanise anticd monoclonal antibody rheumatoid arthritis iii genentech r ocrelizumab humanise anticd monoclonal antibody relapse remit multiple sclerosis ii genentech r pnp inhibitor autoimmune disease transplantation biocryst r sp receptor agonist autoimmune disease transplantation actelion r cellcept mycophenolate mofetil impdh inhibitor lupus nephritis iii aspreva r cellcept mycophenolate mofetil impdh inhibitor pemphigus vulgaris iii aspreva central r antiamyloid peptide antibody alzheimer disease morphosys nervous system r overactive bladder r depression r schizophrenia r anxiety r schizophrenia oncology r mabtherarituxan rituximab anticd monoclonal antibody chronic lymphocytic leukemia relapse iii genentech biogen idec r mabtherarituxan rituximab anticd monoclonal antibody chronic lymphocytic leukemia st line iii r mabtherarituxan rituximab anticd monoclonal antibody indolent nonhodgkin lymphoma maintenance st line iii genentech biogen idec r omnitarg pertuzumab dimerisation inhibitor ovarian cancer ii genentech r omnitarg pertuzumab dimerisation inhibitor metastatic breast cancer ii genentech r tarceva erlotinib egfr inhibitor pancreatic cancer approve genentech osi pharmaceutical file eu r tarceva erlotinib egfr inhibitor nsclc st line maintenance iii genentech osi pharmaceuticals r tarceva erlotinib egfr inhibitor adjuvant nsclc iii genentech osi pharmaceutical r tarcevaavastin egfr inhibitor antivegf monoclonal antibody nsclc st line maintenance iii genentech osi pharmaceutical r erlotinib bevacizumab r tarcevaavastin egfr inhibitor antivegf monoclonal antibody nsclc nd line iii genentech osi pharmaceutical r erlotinib bevacizumab r epothilone solid tumours ii kosan bioscience kos r solid tumour genmab r solid tumour r epothilone solid tumour kosan bioscience kos r xeloda capecitabine fluoropyrimidine gastric cancer file eu r xeloda capecitabine fluoropyrimidine adjuvant breast cancer iii r xeloda capecitabine fluoropyrimidine adjuvant colon cancer combo oxaliplatin iii r xeloda capecitabine fluoropyrimidine metastatic colorectal cancer st line combo iii r xeloda capecitabine fluoropyrimidine metastatic colorectal cancer nd line combo iii r xeloda capecitabine fluoropyrimidine adjuvant colon cancer combo avastin iii r avastin bevacizumab antivegf monoclonal antibody nsclc st line approve genentech file eu r avastin bevacizumab antivegf monoclonal antibody metastatic breast cancer st line combo paclitaxel file genentech useu r avastin bevacizumab antivegf monoclonal antibody nsclc squamous ii genentech r avastin bevacizumab antivegf monoclonal antibody adjuvant colon cancer iii genentech r avastin bevacizumab antivegf monoclonal antibody metastatic colorectal cancer st line combo extension iii genentech r avastin bevacizumab antivegf monoclonal antibody metastatic breast cancer st line combo herceptin iii genentech r avastin bevacizumab antivegf monoclonal antibody pancreatic cancer iii genentech r avastin bevacizumab antivegf monoclonal antibody ovarian cancer st line iii genentech r avastin bevacizumab antivegf monoclonal antibody prostate cancer iii genentech r avastin bevacizumab antivegf monoclonal antibody nsclc previously treat cns metastasis ii genentech r avastin bevacizumab antivegf monoclonal antibody metastatic breast cancer st line combo docetaxel iii genentech r avastin bevacizumab antivegf monoclonal antibody metastatic breast cancer st line combo nontaxane iii genentech r avastin bevacizumab antivegf monoclonal antibody renal cell carcinoma iii genentech r solid tumour r herceptin trastuzumab antiher monoclonal antibody metastatic breast cancer file eu genentech combination hormonal therapy r herceptin trastuzumab antiher monoclonal antibody gastric cancer iii r braf kinase inhibitor malignant melanoma plexxikon respiratory disease r nuclear receptor agonist emphysema ii viral r valcyte valganciclovir inhibitor cmv replication cytomegalovirus extension treatment iii infectious disease r antibiotic bacterial infection ii sankyo cs r polymerase inhibitor hepatitis c ii r hepatitis c maxygen r polymerase inhibitor hepatitis c pharmasset r protease inhibitor hepatitis c intermune optin opportunity altu growth hormone deficiency ii genentech anticd anticd monoclonal antibody nonhodgkin lymphoma ii genentech anticd anticd monoclonal antibody chronic lymphocytic leukemia multiple myeloma genentech apoltrail cancer genentech parp inhibitor malignant melanoma genentech r calcineurin inhibitor renal transplant ii isotechnika isa r alzheimer disease memory pharmaceutical r ef modulator solid tumours ii arqule arq r avastin bevacizumab antivegf monoclonal antibody glioblastoma multiforme ii genentech r avastin bevacizumab antivegf monoclonal antibody adjuvant breast cancer hernegative ii genentech r avastin bevacizumab antivegf monoclonal antibody ovarian cancer nd line ii genentech r avastin bevacizumab antivegf monoclonal antibody gastrointestinal stromal tumour iii genentech r avastin bevacizumab antivegf monoclonal antibody adjuvant rectal cancer iii genentech r avastin bevacizumab antivegf monoclonal antibody metastatic breast cancer nd line iii genentech vegf topical vegf diabetic foot ulcer ii genentech tp colorectal cancer chugai trastuzumabdm metastatic breast cancer genentech r mabtherarituxan rituximab anticd monoclonal antibody primary progressive multiple sclerosis iii genentech r mabtherarituxan rituximab anticd monoclonal antibody lupus nephritis iii genentech r mabtherarituxan rituximab anticd monoclonal antibody ancaassociate vasculitis iii genentech r mabtherarituxan rituximab anticd monoclonal antibody systemic lupus erythematosus iii genentech participation avs antevas nicaraven hydroxyl radical scavenger subarachnoid hemorrhage file jpn chugai ed activate vitamin derivative osteoporosis iii epoch epogin epoetin beta chemotherapyinduce anemia file jpn gm mitemcinal fumarate motilin agonist gastroparesis irritable bowel syndrome ii sg sigmart nicorandil acute heart failure file jpn val valine posthepatectomy ii participation lucentis ranibizumab antibody fragment vegf diabetic macular edema ii genentech xolair omalizumab antiige antibody pediatric asthma iii novartis tanox hae asthma ii beginning pharmaceutical division rd pipeline comprise project include phase initial study healthy volunteer possibly patient new molecular entity nme additional indication twentyfive nme currently phase phase ii efficacy tolerability dosefinde study patient eighteen phase ii phase iii file regulatory review phase iii largescale study patient statistical confirmation ofsafety efficacy bluetype signify indication blacktype additional indication therapeutic protein current january small moleculepharmaceutical result phase iii avastin lung trial hematology nephrology anemia bowhich explore combination result ofsix major phase iii trial ofmircera avastin chemotherapy firstline treat renal anemia involve patient ment ofadvance nsclcare expect chronic kidney disease present halfof major medical conference datum showthat dialysis patient switch directly phase ii study investigate combine herceptin successfully maintenance therapy avastin chemotherapy oncemonthly mircera medicine line treatment herpositive metastatic breast require administration time week cancer show patient time switch achieve complete partial response tumour shrinkage addition study anemia correction recruitment start phase iii trial previously untreated patient chronic averel investigate add avastin kidney disease demonstrate mircera ceptin plus docetaxel firstline treatment give patient twice monthly metastatic breast cancerroche genentech outset clinical development plan investigate combine avastin herceptin mircera chemotherapyinduce anemia adjuvant herpositive breast cancer set cancer patient currently phase ii pro ting ceede plan roche partner currently evaluate rheumatology autoimmune disease mabtherarituxan phase iii trial mainte new clinical result publish use nance therapy follow firstline treatment mabtherarituxan patient rheumatoid product indolent nonhodgkin lym arthritis ra respond therapy phomamabtherarituxan evaluate tnf inhibitor include phase iii programme firstline treat firstradiographic evidence mabtherarituxan ment therapy relapse chronic lym significantly inhibit joint destruction datum phocytic leukemia show continued benefit additional treat ment courses drug development heraa major phase iii trial herceptin product broad group ra patient give woman earlystage breast cancer mild moderate disease respond month continue datum adequately treatment diseasemodifying announce study maturesherceptin antirheumatic drug dmard track evaluate phase iii trial treatment phase iii trial progress ofherpositive stomach cancer actemra develop treatment ra xeloda currently develop adjuvant extensive phase iii programme breast cancer set recruitment patient roche undertake clinical trial large phase iii study ofthe product combine patient currently ongoing docetaxel complete january country patient enrolment complete december omnitarg pertuzumab dimerisation inhibitor develop treatment ocrelizumab anticd humanise mono ovarian breast cancer result recent clonal antibody develop roche phase ii study ofomnitarg plus gemcitabine versus genentech moderate severe rheumatoid gemcitabine advanced platinumresis arthritislike mabtherarituxanocrelizumab tant ovarian cancer encouragingresult target b cellsa fully humanise antibodyit phase ii study drug platinumsensitive potential well toleratedpromise ovarian cancer expect result phase iii datum present american study form basis decision college ofrheumatology conference november progression phase iii development showing ocrelizumab tolerate business report pharmaceutical actemra partner action actemra tocilizumab humanised mono clonal antibody design block inflamma tioncausing protein call interleukin il drug class rheumatoid arthritis ra antibodybase drug originate japan roche chugais codevelopment project actemra selectively target il receptor block activity il protein play major role inflammation characterise ra clinical trial datum indicate actemra dramatically reduce painful disable symptom joint damage ra year rd experience drug con lifecycle team scientific medical tribute global development marketing expertise business specialist roche chugai managing actemra project include collaboration chugai roche excellent phase iii clinical trial centre country chugai successfully market major roche medicine team head roche life cycle leader japan currently seek japanese regulatory maclean hiroyuki ohta senior vice president approval include avastin research head mra unit chugai picture company complementary expertise inter right second right team member est small molecule therapeutic antibody share insight technology actemra story story partner diversity member lifecycle team bring broad range codevelopment project line strength perspective common goal july company sign agreement cover develop commercialise actemra worldwide new chugai compound cancer roche people able learn chugais diabete clinically active test dose extensive metabolic disorder phase iii clinical development programme type adult onset diabete recognise planned start early global epidemic estimate mil lion people worldwide disease additionroche develop run oral p roche currently investigate dif map kinase inhibitor moderate severe ra ferent biological target screen drug candi inhibition enzyme p map kinase reduce date production key mediator inflammation currently phase ii clinical testing r blood glucose control depend largely secre potential offer increase safety efficacy tion insulin beta cell pancrea easy administration compare currently response fluctuation glucose levelshowever available dmard relate glucose production business report pharmaceutical building future world leader biotech manufacturing capacity roche group continue invest inthe future meet rise demand ther apeutic antibody product roche building stateoftheart biotech facility produce avastin herceptin basel switzerland penzberg germany project represent investment million swiss franc facility build tight schedule ensure fully operational manufacturing group market project team site share strong sense urgency employ fasttrack project budget ahead schedule approach mean design engineering construction building complete phase place concurrently result significant year equipment instal time saving commenting advantage daniel year final commission qualifi riekert picture standing project manager cation place final regulatory inspec basel say fasttrack approach make possible tion speed facility complete complex building project fast operational year total remark ve accumulate lot experience able say penzberg project manager claus herrmann area share engineering colleague seat right show commit com genentech chugai knowhow benefit pany ensure biotech medicine avail entire roche group able patient tightly control liver glucokinase closely mimic action natural human enzyme play key role organ hormone glp offer potential weekly target pathway r roche long administration intervalsunlike glp inclass oral glucokinase activator design analogue r far provoke anti provide well control type diabetes body response ofthe people give drug current standard therapy r currently phase iib study currently preparedwith phase ii clinical trial roche develop administration plan early compound act glucokinase component glucose metabolism potential dyslipidemia treatment type diabete lack ofhighdensity lipoprotein cholesterol hdl c good cholesterol associate july roche announce exercise increase risk cardiovascular disease r option licensedevelop market r bim license japan tobaccois cholesteryl ester longacting glucagonlike peptide transfer protein cetp inhibitor unique glp analogue develop ipsen type mechanism ofaction design raise level diabetes r similar structure ofhdlcphase ii study near completion business report pharmaceutical datum indicate compound good roche pharmaceutical currently invest safety profile desire effect hdlc billion swiss franc manufacturing blood lipid fatsthe result stud infrastructure project include major biotech ies form basis decision facility produce active ingredient entry phase iii testingunlike development avastin herceptin basel switzerland compound class recently penzberg germany new formulation filling discontinue company r packaging logistic facility injectable associate adverse cardiovascular infusable medicine kaiseraugst switzerland change increase blood pressure mannheim germanyand facility toluca give patient monotherapy combina mexico formulation highly potent tion statinsnor r affect cardiovascu medicine xeloda lar parameter animal model virology chronic infection hcv genotype difficult type ofhepatitis c treatthis viral subtype find large subgroup patient hepatitis conly ofpatient hcv genotype respond current treat mentsand experience severe effectsto meet need new treatment option roche novel antihcv agent clinical devel opment r currently phase ii potent inhibitor hcv polymerase enzyme essential replication virus addition compound partnership pharm asset maxygen enter phase clinical testing central nervous system disease disease central nervous system represent great unmet medical need world wide large segment global pharmaceutical marketroche currently project early clinical development area include promising phase compound alzheimers diseaseschizophrenia depression manufacturing infrastructure yearsroche systemati cally develop manufacturing infrastructure line ongoing change group prod uct mix meet current expect demand new biologic medicine addition ensure manufacturing operation remain effi cientcosteffective environmentally compati ble continually incorporate improved technology update process line good practice business report diagnostic division brief sale million chf operating profit exceptional item millions chf publish annual report number employee key figure change change millions chf chf local currency sale sale diabetes care centralize diagnostic molecular diagnostic near patient testing apply science ebitda operate profit research development exceptional item diagnostic executive committee january severin schwan ceo division roche diagnostic perolof attinger platform support silvia ayyoubi human resource manfre baier apply science christian hebich finance service daniel oday molecular diagnostic tiffany olson north america volker pfahlert professional diagnostic burkhard g piper diabetes care jrgen schwiezer emea europe middle east africa latin america robert yates business development business report diagnostic division sale region roche diagnostic world leader invitro diagnostic product test human body europemiddle east fluid tissue obtain information africa diagnosis prevention treatment disease japan andit supplier innovative solution asiapacific medical biotechnology researchthe division large grow product portfolio range iberia home blood glucose monitoring product latin america people diabete pointofcare test north america device use doctorsoffice highthrough laboratory system hospital stateof italic growth rate theart instrument genetic research october food drug administration division rd manufacturing facility fda lift import alert bar sale austria germany switzerland united accuchek insulin pump disetronic medical state augment extensive network systemswith new accuchek spirit pump alliance partnership give division broad available world large infusion system access important new technology market roche expect strengthen capability help today healthcare market leadership diabetes care bettersafer costeffective provide scientist tool need discover tomor divisional operating profit exceptional row medical advance item decline billion swiss franc result margin decline percentage pointsthis primarily increase invest result ment launch activitiesimpairment charge intangible asset low royalty income roche diagnostic remain global leader licencesthe impairment charge mainly relate increasingly competitive market intangible asset record follow disetronic market share divisional sale increase acquisition decline royalty income year local currency swiss follow worldwide expiry ofthe foundational franc dollarsfuelle new product patent polymerase chain reaction pcr tech launch slightly market nology country outside usebitda growth rate centralize diagnostic near patient testing apply science unit state growth rate local cur main contributor growth roche diabetes rencie care sale grow earning exceptional item financial income financing cost tax depreciation amortisation including impairment business report diagnostic total billion francsor salescom united states customer access pare complete roche portfolio insulin delivery industry average product fda lift import alert accuchek insulin pump october customer response accuchek spirit business area pumpwhich available coun trieswa positive month diabetes care market roche diabete care insulin delivery business post doubledigit growth roche diabete care supply broad range blood glucose meter insulin delivery system centralize diagnostic well diabetes managementmonitore system integrate lancetstest strip software laboratory workload increase store analyse datum increasingly grow demand test detect disease early important roche diabetes care portfolio target therapiesat time improve glucose control hospitalbase commercial laboratory usersin addition offer great convenience pressure contain cut cost roche activity aim integrate glucose monitor centralized diagnostic supply instrument datum management insulin delivery testsdata management software service ongoing day result system enablelaboratorie cope challenge closely mimic way healthy pancrea regu simplify workflow enhance productivity late blood glucose level efficiency roche diabetes care remain global market roche centralize diagnostic post leader follow growth abovemarket sale growth remain halfyear sale rise quarter industry leader market share fourthfullyear sale rollout ofthe mediumthroughput cobas previous year analyser series european launch cobas c analyser customer small test new accuchek product portfolio make volume mark important step business easy people diabetes manage strategy centre make clinical chemistry condition accuchek spirit insulin immunochemistry testing simple effi pumpit include accuchek aviva accu cientan application marketing approval chek blood glucose monitoring system cobas c analyser submit fda accuchek compact plus allinone system late cobas analyser series isafully integrate aglucose meter automatic test automate integrate system capable handling strip dispenser lance devicealso new routine test perform accuchek multiclix lance devicewhich feature dailyby mediumvolume laboratorythank unique preloade lancet drum safe flexiblemodular designit configure exactly convenient comfortable blood sampling customer individual need new module market uptake product strong add time need grow spur additional sale growth helping set decline sale oftheaccuchek advantage sys immunoassay sale continue grow significantly temone roche diabete care successful fast market advance product nearly decade rollout new thank product like elecsys probnp monitor system complete mid elecsys troponin assay cardiac disorder launch oftheaccuchek compact plus sale ntprobnp marker grew help north america accuchek aviva japanthe additional approval elecsys probnp entire new family accuchek product assay use assess risk cardiac event available worldwide patient stable coronary artery disease business report diagnostic consolidation flexibility cobas tergooi hospital neighbouring town hilversum blaricum netherlands recently merge bed eric vermeer picture frit fernhout visionary young doctor hospital charge europe reference laboratory equip instrument roche cobas analyser series ambition year netherlands good reference labs june laboratory install new analyser handle grow year hope important reason choose cobas adapt expand system cope analyser series consolidation allow high workload will not problem form clinical chemistry immunochemistry testing add cobas e cobas c single platform say dr vermeer space module simple saving significant relatively large clinical chemistry analyser plus improve workflow efficient use staff system immunoassay today new work lab short turnaround time cobas instrument instead capable serve low cost advantage dr vermeer backup intend use extra space dr fernhout experience firsthand expand range test laboratory offer switch cobas analyser series staff like standardise userfriendly interface selling point system flexibility software switch master add dr fernhout volume test order different operator interface day molecular diagnostic roche molecular diagnostic maintain lead e market share sale advance roche molecular diagnostic develop com yearvirology large segment mercialise innovative highly sensitive system sale grow line virology test reliably detect bacteria virus market pathogen patient sample donate bloodtissue organsthese product use tech steppedup sale effort combine cobas nologie directly detect genetic material ampliprepcobas taqman platform menu dna rna ofinfecte pathogen hiv viral load test hiv hepatitis b c hepatitis virus provide fast virus hbv hcv drive product sale result test base bodys immune help roche molecular diagnostic maintain response infection business area market share europe offer fully auto work additional genebase test facilitate mate sample preparation analysis cobas differential diagnosis treatment selection ampliprepcobas taqman enhance laboratory number ofother disease productivity test result integrityfda review business report diagnostic hiv viral load test platform monitor coaguchek xs plus healthcare advanced roche prepare submit professionalscommenced european rollout marketing application hcv test january october respectively coaguchek xs fda early monitor viral load receive fda approval quarter virus patient blood impor launch plan quarter tant way ofassesse disease progression treat system provide patient take oral ment response anticoagulant health professional accu rateonthespot result single drop ofblood june roche begin roll new fully successful launch strengthen roche automate cobas modular blood screen global leadership coagulation monitoring system coba taqscreen mpx multiplex test europe cobas taqscreen mpx test roche near patient testing clear leader simultaneously detect hivhcv hbv hospitalbase blood glucose monitoring donate blood receive ce mark conformit accuchek inform meter accuchek advan europenne certification march prod tage accuchek sensor test strip core uct available european country product drive roche grow market share filings multiplex test separate segment west nile virus test cobas system plan apply science year additional large laboratory life sciences encompass discipline range sign offer amplichip cyp test biology genetic proteomic medical microarraybased test detect genetic varia research major disease area cancer tion affect way patient respond virology roche apply science supply broad treatment widely prescribe drug grow array instrument highly spe cific test reagent test kit research applica roche prepare submit filing fda tion diverse market half test detect geno type low intermediate highrisk strain roche apply science sale grow human papillomavirus hpvpersistent infection nearly twice market growth rate growth certain hpv genotype know risk factor drive primarily lightcycl cervical cancer instrument genome sequencer system lightcycler highly versatile highthrough near patient testing gene expression mutation analysis plat form base polymerase chain reaction roche near patient testing supply product pcr technology pioneer rochethe inno use outside central laboratory example vative genome sequencer systemfirst launch physiciansoffice patientsbedsidesportable late mark roche successful entry diagnostic monitoring device rapid simple attractive dna sequence research market toperform test advanced software support sequence long dna fragment entire clinical decisionmaking point ofcare genome time fast conventional com core product group mercially available instrument business area reinforce market leadership roche apply science supplier indus overall sale rise yearhelpe trial reagent substrate account continue trend decentralised major sale revenue product test important contributor growth roche near patient testing new coagulation monitor systemscoaguchek xs patient self business report diagnostic major product launch business area product diabetes care new accuchek meter offering improve feature set design accuchek smart pix small easytouse device reader transfer data accuchek pump blood glucose meter user pc centralize diagnostic cobas analyser series integrate clinical chemistry cobas c module immunoassay cobas e module platform midvolume laboratory design easy onsite expandability cobas c standalone clinical chemistry electrolyte analyser extrasmallworkload laboratory cobas solution laboratory information system support step laboratory testing order entry result report feature connectivity sample management quality control validation capability molecular diagnostic cobas taqscreen mpx multiplex test multiplex test detection hiv group hiv hepatitis b c cobas system screen blood plasma organ tissue living donor lightcycler septifast test ce rapidly reliably detect identifie pathogen responsible bloodstream infection near patient testing coaguchek xs plus handheld coagulation monitoring system professional use coaguchek xs handheld coagulation monitoring system selfteste apply science lightcycler instrument new format software module extend system broad range application research development regimen business area explore project range safe convenient lance roche diagnostic invest million device insulin guidance software decision swiss francsor salesin research devel support program design help physician opment molecular diagnostic immuno patient well treatment decisionsa second chemistry diabete care business account generation continuous glucose monitoring system large share ofexpenditure project currently develop ment diabetes care centralize diagnostic roche diabete care pursue continuous improvement integrate blood glucose moni follow rollout cobas tore integrated system reduce number analyser series roche centralize diagnostic different device step require track blood prepare launch second cobas modular glucose level make easy people platform new platformwhich diabetes adhere diabete management market cobas analyser seriesis gear business report diagnostic key product launch schedule business area product diabetes care accuchek performa blood glucose monitoring system give test result second perform extensive quality check include advanced datum management feature accuchek easytouse customisable pcbase data management software design wide range use download datum perform detailed analysis people diabete healthcare professional new accuchek compact plus blood glucose monitoring system improve userfriendly design ergonomic user interface professional diagnostic cobas e standalone immunochemistry analyser small mediumworkload laboratory successor elecsys mpa connectivity cobas analyser series connectivity hardware software cobas modular preanalytic module offer laboratory total automation sample preparation result additional configuration cobas analyser series combine cobas c cobas e modules cobas cobas cobas cobas new configuration design suit wide range laboratory workload cobas c system standalone clinical chemistry analyser small mediumworkload laboratory mylabview portal online benchmarking result obtain serum work area analyser cobas solution central lab datum management system wammiddleware instrument interface consolidation provide resultrelate reagent test information cobas solution work area manager hospital point care product update release periodically cobas h portable system bedside fixedlocation cardiac testing test menu roche cardiac assay cobas h handheld meter measure cholesterol triglyceride lactate blood design professional selftesting environment molecular diagnostic cobas taqman hbv test automate realtime pcr amplification quantitation hepatitis b virus cobas taqscreen wnv test cobas system automate realtime pcr detection west nile virus donate blood plasma cobas ampliprepcobas taqman hiv hbv hcv test automate realtime pcr amplification quantitation hiv hepatitis b c virus hiv hiv hbv hcv japan apply science broad rollout genome sequencer flx nextgeneration dna sequence system fast costefficient roche ultrafast genome sequencer include roche centralized diagnostic roche near patient testing business report diagnostic need oflowworkload laboratoriesit com ofserious psychiatric diseasesalso roche prise cobas e immunoassay system explore use amplichip cyp test schedule launch early cobas identify variation cypd gene c clinical chemistry system follow inhibit metabolism conversion breast thesecond halfofthe yearthe cobas e system cancer drug tamoxifen body active provide result critical assays little form woman cypd variant nineminute poor metaboliser tamoxifen show receive therapeutic benefit proteomic research roche identify drug novel biomarker candidates colorectallung breast cancer rheumatoid arthritis near patient test molecular diagnostic roche near patient testing continue renew broad product portfolio launch ofroche molecular diagnosticstop prioritie new instrument test cardiovascular param develop secondgeneration multiplex blood eter hospital go forward overall screening assay indicate focus develop instrument offer unit blood positive viral contamination great ease ofuse test consolidationin partic identify virus present hiv ular effort aim address need group ohivhbv hcvthis automation intensive care unit eliminate need separate viral target resolu setting frequent testing require tiontestingwhich require firstgeneration multiplex assay screen effi applied science cient development activity aim improve oncology phase rochesponsore throughput sample handle international research study show successful lightcycler instrument genome microarraybase analysis leukemias distin sequencer system ongoing nextgenera guishe different subtype accurately conven tion sequence system genome sequencer flx tional method subject interlabora available halfofroche tory variationidentifye leukemia subtype apply science plan add new research patient critical select good avail reagent product automate cell analysis able treatmentdata study toit portfolio determine gene sequence include amplichip leukemia microarray develop ment potentially provide physician single standardised test diagnose leukemia subtypesin additionroche develop ing amplichip p test identify mutation p gene disable normal cell function allow cancer cell proliferate mutation p find virtually tumour type test day help assess prognosis patient cancer select therapy well suit individual need roche receive initial datum large scale study correlating variation cyp gene cypd cypc clinical come treatment cost inpatient treatment business report little brother catch flu get holiday business report tamiflu stop flu track tuesday late februarythe weather reportsaid snow condition idealand week accommodation bookedkristina anddiana day school family leave annual skiing tripunfortunatelyit brother niklas suddenly illrapidly devel oping fever headacheand instead hisusual happyactive selfthe sixyearold show interest rest alert recent news story influenza outbreak germanythe children mother immediately take niklas family pediatricianhe promptly diagnose flu andpre scribe treatment tamiflu oseltamivir inadditionsince family member bynow probably expose flu virus doctor advise tamiflu prophy laxisthe family start take medicine dayafter mother show girl niklas measure correct dose oftamiflu suspension themselvesusing dispenser provide everyone reliefnikla rapid recovery prophylaxis successful family come fluthe follow saturdaythe family able mountain plan prevention influenza disrupt holiday plan illness devastating consequence year seasonal influenza affect million people worldwide death attribute disease child elderly risk people health compromise condition treat initial case tamiflu give tamiflu prophylaxis family member prove effective prevent transmission influenza household business report corporate governance remuneration report corporate governance roche meet relevant corporate governance mauro elect new member roche requirement particular complie high governing body term applicable law swiss stock exchange yearsrolfhnggiwho serve vicechair swx swiss exchange directive include man ofthe board ofdirector decline commentary thereto swiss code well stand reelection agm practice corporate governance promulgate swiss business federation economiesuisse organising meeting immediately follow company internal governance frameworkpar agmthe board director adopt change ticularly article incorporation bylaw committee structure committee member embody principle need ensure ship show table inparticu company business manage super larthe audit corporate governance commit vise manner consistent good corporate tee reconstitute audit committeeand governance include necessary check responsibility corporate governance sustain balance ability report legal compliance safety health environmental protection print annual report contain select link previously audit corporate roche website wwwrochecomreader governance committee remitwas transfer provide snapshot newly establish corporate governance company report date direct sustainability committeechaire andreas oeri source consult time finance investment committee dis uptodate information corporate govern solve remit transfer new audit ance rochewherea annual report cover committeechaired deanne julius single financial year end december website contain information ofa permanent annual general meeting roche nature late roche news amend shareholders march board ofdirec ments company article incorporation tor propose pius baschera wolfgang bylaw change curricula vitae ofthe ruttenstorfer elect additional member member ofthe board ofdirector corpo board rate executive committee publish timely fashion websitewhere access pius baschera swiss citizen bear look information chairman board hilti corporation start ofafter completing degree mechanical engineering management study board director swiss federal institute oftechnologyzurich pius baschera join hilti hold num th annual general meeting agm ber position united states europe roche hold ltdon february deanne juliuspeter brabeckletmathe horst teltschik elect additional fouryear term board directorsin additionbeatrice weder di httpwwwrochecomhomecompanycomgovhtm business report corporate governance board director january leftjohn bell beatrice weder di mauro peter brabeckletmathe brunogehrig andrhoffmann franz b humer lodewijk jr de vink deanne julius walter frey andreasoeri horst teltschik year birth term end elect board director dr franz b humer f chairman prof bruno gehrig c e vicechairman independent lead director andr hoffmann c e vicechairman prof john irving bell c e peter brabeckletmathe e lodewijk jr de vink c e walter frey b e dr deanne julius b e dr andreas oeri e prof horst teltschik b e prof beatrice weder di mauro b e secretary board directors dr gottlieb keller honorary chairman board directors dr fritz gerber corporate governance sustainability committee presidiumnomination committee b audit committee e nonexecutive director c remuneration committee f executive director committee chairperson january business report corporate governance appoint cfo information relate corporate chairman ofthe executive boarda position governance step chairman ofthe board january pius baschera group structure shareholder honorary professor swiss federal institute roche operate business organise technologyzurich divisionspharmaceutical diagnostic pharmaceutical division comprise wolfgang ruttenstorferan austrian citizen bear business segment roche pharmaceutical graduate vienna university eco genentech chugai nomic business administrationsince diagnostic division consist follow ceo chairman ofthe executive board e business areasapplie sciencediabete omv aktiengesellschaftin addition head care centralize diagnostic molecular diag companys natural gas chemical busi nostic near patient testingbusiness activi ness wolfgang ruttenstorfer join omv tie carry group subsidiary appoint executive board associate company significant subsid austria deputy iarie associate company list minister finance return omv finance report note roche group wolfgang ruttenstorfer recognise expert consolidated financial statement subsidiary emerge market eastern europe associate companiespage middle east major shareholder list finance report note roche group consolidate financial statement equity corporate executive committee attributable roche shareholdersand relate party page note severin schwan join corporate executive financial statement roche holding ltd committee new ceo division roche diag nostics january heino von prondzynski andr hoffmann vicechairman board ceo division roche diagnosticsresigne director andreas oeri chairman roche end theboard corporate governance sustain ability committee serve respective effect january burkhard g capacities board committee pipereduard holdenerpeter hugrolf schlpfer representative shareholder group osamu nagayama appoint member pool voting right receive remunera roche enlarge corporate executive committee tion set forth remuneration report relationship exist effective january pascal soriot head shareholder pool voting right pharma strategic marketing head crossshareholding commercial operation pharmaceutical division join enlarge corporate exe capital structure cutive committee information roche capital structure pro vide finance reportnote finan cial statement ofroche hold ltd additional detail contain article incorporation ofroche hold ltd change equity detailed finance report note financial statement roche holding ltd httpwwwrochecomhomecompany comgovcomgovartihtm business report corporate governance corporate executive committee december leftjonathan kc knowles pierre jaccoud severinschwan burkhard g piper william burns eduard holdener franz b humer peter hug erichhunziker rolfschlpfer gottliebakeller osamu nagayama year birth position corporate executive committee dr franz b humer chairman ceo roche group dr erich hunziker chief financial officer deputy head corporate executive committee william burns ceo division roche pharmaceutical dr severin schwan ceo division roche diagnostic prof jonathan kc knowles head global research dr gottlieb keller head corporate service human resource enlarge corporate dr eduard holdener head global pharma development executive committee dr peter hug head pharma partner burkhard g piper head business area roche diabetes care pascal soriot head commercial operation pharmaceutical division rolf schlpfer head corporate communication osamu nagayama president ceo chugai secretary pierre jaccoud head chairmans office corporate executive committee statutory auditor kpmg klynveld peat marwick goerdeler sa roche holding ltd principal auditor john morris group auditor compliance officer dr andreas greuter business report corporate governance company share capital article incorporation swiss francsdivide fully pay roche holding ltd minute th bearer share nominal value swiss annual general meeting roche holding ltd franc eachthere restriction exer hold february cise voting right share chairman board directors franz b depositshare vote restric humer continue director tion serve executive capacity roche authorise conditional capital majority seat board director addition nonvoting equity secur hold independent director itie nes issue bearer form nonexecutive member form share capital board ofdirector member ofroche confer voting right ne confer corporate executive committee serve right share participate avail executive capacity group subsidiary able earning liquidation proceed financial year precede follow repayment ofthe share capitalroche current reporting period ne right pertain thereto include internal organisation ofthe board ofdirec provision protect interest ne tor division authority responsi holder describe article bilities board managementthe incorporation ofroche holding ltd remits ofthe board committee informa information debt instrument tion control mechanism available issue outstanding bond pro board dealing corporate manage vide finance report note ment govern bylaw roche group consolidated financial statement board director roche holding ltd debt organise ensure group busi additional information employee stock ness conduct responsibly option provide finance reportnote focus longterm value creation end roche group consolidate financial roche board delegate certain responsi statement employee stock option bilitie committee composi equity compensation benefit tion chairperson january roche issue option apart employee describe stock option stocksettle stock appreciation committee presidium right ssar option issue connec chair independent director tion debt instrument article ofthe bylaw option award employee board director independent lead debt instrument issue director discretion effect roche share capital request ofany memberconvene board meeting chairman presentthe roche board board director corporate executive meet year assess chairman committee formancethis meetingwhich attend information member board chairman chair independent director include year lead director elect year term end member corporate executive httpwwwrochecomhomecompanycomgovhtm committee list page httpwwwrochecomhomecompany curricula vitae information includ comgovcomgovartihtm httpwwwrochecomhomecompany ing information board memberships comgovcomgovgvhtm available internet httpwwwrochecomhomecompany annual general meeting elect member comgovcomgovbylawshtm board director stagger election httpwwwrochecomhomecompany nominee vote separately comgovcomgovcomhtm business report corporate governance board ofdirector regularly conduct self chairman secretary board assessment ofit performance director present board meeting board director establish system board discuss ofcontrol oversee audit com formance remunerationthe member mittee corporate governance corporate executive committee sustainability committee consist ofthe fol invite attend report person low element agenda item concern themwhen report financial operating risk situation warrant member enlarge internal audits corporate executive committee compliance officer invite attend board committee invite safety health environmental protection chairman ofthe board corporate department executive committee member deliver report corporate sustainability committee committee meeting elect commis scientific ethic advisory group seag sion independent expert report issue relate genetic genetic engi service consultant risk management neere establish system subject continuous review year blackout period impose review finding present audit senior employee prohibit committee boardinternal audit regu trading company stock follow larly brief audit committee reference blackout period effect ongoing audit report member internal january february audit attend audit committee meeting april april external auditorsfor information exter july july nal auditorssee october october management contract fall blackout period change chair mean ofsubsection ofthe swx man board director circumstance directive information relate corporate warrant governance board director meet meetingseach hour lengthonce remuneration shareholding loan fullday meetingand threeday detail remuneration sharehold official trip include additional board ing loan set forth remuneration director meet board committee report page meet follow presidium ofthe board ofdirector participatory right shareholder nomination committeefive meeting participatory right shareholder approxhour define roche article incorporation audit committeethree meeting roche share issue bearer approxto hour norestriction admission annual general corporate governance sustainability meetingswith exception share committeetwo meeting approx hour deposit specify period date meeting admittance card remuneration committeetwo meeting issue shareholder namea provide approx hour article incorporation audit corporate governance committee shareholder elect represent discontinuedone meeting approx hour shareholder annual general meet finance investment committee discon ing article incorporation contain tinuedone meeting approx hour restriction exercise vote rightsand figure indicate actual length meeting include director extensive premeete prepara httpwwwrochecomhomecompany tion postmeete followup activity comgovcomgovartihtm business report corporate governance quorum requirement stipu late compliance swiss code millions chf ofobligation audit service article incorporation auditrelated service shareholder represent share nominal tax consultancy service value ofat million swiss franc request total placement item agenda annual general meetingthis group auditor statutory auditor later day date ofthe meeting elect year annual general meeting change control defensive measure ernst young ltd receive follow remu article incorporation contain provi neration service auditor sion mandatory bid rule swiss law genentech chugai apply changeofcontrol clause component remuneration base roche millions chf ne terminate event genentech chugai audits acquisition vest period restriction consult service provide preexisting award removedso genentech chugai option immediately exercise total relationship group auditor information policy statutory auditor provide article incorpora annual general meeting roche hold tion corporate notice publish ing ltd february shareholders swiss official gazette commerce vote appoint kpmg klynveld peat marwick daily newspaper designate board goerdeler sa kpmg group auditor directors basler zeitungfinanz und wirtschaft statutory auditor information long lagefile tempsneue zrcher zeitung current group auditor principal auditor roche report halfyear fullyear result serve capacity provide business report publish print online group auditor statutory format medium event addition auditor participate audit committee meet detailed thirdquarter sale figure ingsthe auditor write oral report publish year april october result oftheir auditsthe audit commit current list ofpublication date available tee oversee assess auditor make english german internet recommendation board information relevant information documentsinclud responsibilitie audit committee ing medium release investor update article bylaw group presentation analyst investor conference auditor statutory auditor participate available internet publica meeting ofthe auditaudit corporate tion order emailfax telephone governance committee baselwebmasterrochecom report ofthe group statutory auditor tel fax find respectivelyof year finance report httpwwwrochecomhomecompany comgovcomgovbylawshtm kpmg receive follow remuneration httpwwwrochecomhomecompany service group auditor statutory comgovcomgovartihtm auditor roche holding ltd roche httpwwwrochecomhomemediamedeventshtm financial company httpwwwrochecomhomeinvestor invnewsupdhtm business report corporate governance contact address investor relation fhoffmannla roche ltdinvestor relation corporate finance baselswitzerland tel fax additional information include detail specific contact person available internet compliance officer compliance officer commit ensur e roche corporate principle consis tently comply roche group serve contact person shareholder employee customer supplier general public issue relate implementation compliance principle employee party aware violation roche corporate principle bring attention manager supervisor report compliance officer andrea greuter direct phone number email andreasgreuterrochecom disclosure treat confidential employee disclosure penalise company sobut immune prosecution legal violationsthe com pliance officer report regularly corporate governance sustainability committee nonapplicabilitynegative disclosure expressly note information contain mention nonapplicable omission construe negative declaration according requirement ofthe swx swiss exchange corporate governance directiveinclude commentary httpwwwrochecomhomeinvestor invcontacthtm business report remuneration report remuneration report roche success depend ability dedica stocksettle stock appreciation right tion ofit peoplerecognition ofthis founda tion ofour remuneration policy systemin stocksettle stock appreciation right ssar remuneration report inform shareholder introduce roche january interested member ofthe general public establish uniform system remuneration remuneration pay director senior rochessars entitle holder bene executive integral annual fit financially increase value reportthis remuneration report submit roche nonvoting equity security approval annual general meeting grant date exercise datedetaile informa tion available remuneration policy performance share plan roche revise global remuneration policy ofa framework ofemployee policy member ofthe corporate executive commit aim motivating retain current employ tee member senior management ee attract talented new one help individual worldwide participate roche employee perform consistently high performance share plan psp estab levelsour remuneration policy design fos lishe beginning period ofthree ter value creation reinforce culture year performance cycle end formance innovation apply non second cycle psp managerial employee managerskey year principle underpin policy start adjust plan design intro focus value creation ducedunder new arrangement onethird pay performance nonvoting equity security nes enable employee share company award new threeyear performance cycle success start yearin contrast successive fairness transparency remuneration year cycle old plan designin decision overlapping performance cyclespsp remuneration target market median level psp balanced mix oflong shortterm remu increase total awardfor detail ofthe psp neration component marketcompetitiveness year psp establish award stocksettle stock appreciation right roche security share nesinclude performance share plan support prin dividend yield double value ciplesthese remuneration component link outperform ninefold value growth company financial performance com deliver peer set major pharmaceutical mercial success align interest diagnostic company roche employee ofthe stockholder peer set abbott laboratories amgen astrazeneca bayer beckton dickinson biogen idec bristolmyers squibb eli lilly glaxosmithkline johnson johnson merck novartis pfizer sanofiaventis scheringplough takeda wyeth business report remuneration report tsr development december value chf invest st week january period end december price translate constant chf exchange rate remuneration corporate executive remuneration additional compensation pay committee nonexecutive member board director total swiss franc previous remuneration committeewhich comprise year swiss francswith exception entirely independent external member vicechairman independent lead board ofdirectorsset remuneration mem directorall members ofthe board ofdirector ber corporate executive committee cash receive remuneration payment bonus option stocksettle stock appreciation right policy decision pen nonexecutive member ofthe board ofdirec sion benefitsthe term ofthe performance share tor award share nonvoting plan determine board director equity securitiesstocksettle stock appreciation act recommendation remu right stock option neration committee december hold unvested option award previous year follow detailed review include market comparison remuneration committee addition rolf hnggi receive pro rata conclude roche current remuneration swiss franc serve policy continue appropriate suitable board director january february achieve intend objective mr hnggiwho nonexecutive direc torresigne board follow page provide detailed information remuneration pay member john bell oneyear sabbatical leave board director member university oxford august corporate executive committee spending year rocheroche pay figure previous year personal family expense profbell incurs relation stay switzerland include remuneration insurance cost expense total swiss franc remuneration member board director member board director receive remuneration show table serve board business report naj rpa yluj tco naj rpa yluj tco naj rpa yluj tco naj rpa yluj tco naj rpa yluj tco ce roche ne roche share peer set price price index stock optionsstocksettle stock appreciation right remuneration report remuneration member board director additional compensation remuneration member remuneration committee member board director chf chf fb humer b gehrig hoffmann ji bell p brabeckletmathe ljr de vink w frey da julius oeri h teltschik b weder di mauro total swiss franc committee membershipyear member presidium vicechairman remuneration pay fb humer executive member board director deduct agree salary remuneration member corporate executive committee remuneration serve independent lead director vicechairman board prorate remuneration serve member board director january february vicechair man board period march december prorate remuneration period march december remuneration member corporate executive committee cash payment chf annual salary annual salary annual salary bonus bonus bonus fb humer wm burn e hunziker ga keller jkc knowles schwan total b stock optionsstocksettle stock appreciation right ssar ssar ssar stock option value chf value chf value chf fb humer wm burn e hunziker ga keller jkc knowles schwan total stock optionsstocksettle stock appreciation right blackschole value describe stock optionsstocksettle stock appreciation right business report remuneration report roche pay swiss franc retirement member corporate executive committee policy john bell additionally receive annual expense allowance swiss franc chief executive officer horst teltschik receive honoraria include receive annual expense allowance expense amount euro swiss swiss francsin member ofthe executive franc serve board roche committee receive expense allowance totalling subsidiary germany swiss franc otherwiseno additional remuneration pay heino von prondzynski step member ofthe board ofdirector corporate executive committee december assist transition remuneration member successorheino von prondzynski resign corporate executive committee roche effect december general provision assign authority deci pay salary swiss francshe sion corporate executive committee remuner receive bonus swiss franc respect ation remuneration committee expense allowance swiss board director outline franc remuneration report c performance share plan member corporate executive member ofthe corporate executive commit committee receive salary bonuse stock tee member senior management optionsstocksettle stock appreciation right individual worldwide participate nonvoting equity security show table performance share plan psp performance share plan psp total estimate total estimate value psp award value psp award target number target number ne psp ne psp chf chf fb humer wm burn e hunziker ga keller jkc knowles schwan total estimate value calculate yearend price december chf nonvoting equity secur ity ne base number ne originally target subject change number value ne awardable plan december spread relevant period time ie year board director vote actual allocation ne originally target december accord tsr growth achieve estimate value calculate yearend price december chf nonvoting equity secur ity ne base number ne originally target subject change number value ne awardable plan december spread relevant period time ie year board director vote actual allocation ne originally target december accord tsr growth achieve estimate value calculate yearend price december chf nonvoting equity secur ity ne base number ne originally target subject change number value ne awardable plan december spread relevant period time ie year board director vote actual allocation ne originally target december accord tsr growth achieve business report remuneration report roche performance roche tsr average tsr peer group company jan dec jan dec total shareholder return tsr value chf invest january roche market capitalisation billion chf roche security chf nonvoting equity security ne share price translate constant chf exchange rate tsr stock price appreciation plus dividend psp moved overlap threeyear ber corporate executive committee performance cycle new cycle beginning show table board ofdirec year cycle tor decide actual level ne cash progress psp psp equivalent award cycle provision ofthis plana number ofnon close voting equity security nes reserve financial yearsrespectively participant cycle number security actually award depend end year yearrespectively extent investment roche securi psp psp tie share ne outperform average formance cycle base threemonth return investment security issue move average constant exchange rate roche peer set ofcomparator companiescomparison rank compare peer set base securitiesmarket price divi company operate industry dend yieldsieon total shareholder return tsr reduce effect ofany shortterm market fluc roche market value rise billion tuationssecurity price average billion swiss franc period january months october december prior start december increase billion performance cycle month swiss franc dividend total bil october december end cycle lion swiss franc billion swiss franc roche security perform well billion swiss franc distribute peer set addition roche tsr increase cycle indirect benefit board director elect increase employer contribution maximum nes award twofold social security scheme pension plan event investment roche security underperform average return deliver peer companiesfewer ne award ne reserve plan mem business report footnote footnote remuneration report indirect benefit pension fundsmgb ahvivalv roche connect chf chf chf fb humer wm burn e hunziker ga keller jkc knowles schwan total mgb stiftung der f hoffmannla roche ag fr mitarbeitergewinnbeteiligung employee profitshare foundation supplement occupational pension benefit ahvivalv swiss social security programme provide retirement disability unemployment benefit owe amendment switzerland federal occupational old age survivor disability pension act bvg contri bution behalf franz b humer limit swiss franc exist contractual obligation result additional provision swiss franc company groupwide employee stock purchase plan roche pension total swiss franc pay connect respect member corporate corporate executive committee executive committee show table member indirect benefit franz bhumererich hunzikerwilliam mburn roche connect voluntary stock purchase plan jonathan kcknowle receive total usd offer employee opportunity buy roche swiss franc serve nonvoting equity security ne chugai board erich hunziker william burn equal oftheir annual salary discount jonathan kcknowles genentech nes purchase plan subject hold board decline remuneration serve ing periodwhich switzerland year capacity roche pay swiss franc occupational additional remuneration pay pension contribution swiss franc current member corporate employer ahv social security contribution executive committee swiss franc roche connect contribu tions heino von prondzynski f high total remuneration chairman ceo franz bhumer mem e remuneration emolument loan ber ofthe board member ofthe corporate corporate officer executive committee high total remu neration remuneration member gottlieb keller repay mortgage loan corporate executive committee fhoffmannla roche ltd pension fund subject change allocation computation end relate threeyear performance share plan psp period franz b roche pay severin schwan swiss franc humer salary follow foronetime relocation housing cost business report remuneration report high total remuneration chf cash payment stock optionsssar blackschole valueat grant minus performance share plan pension fundsmgb roche connect total value blackschole value describe stock optionsstocksettle stock appreciation right remuneration member corporate executive committee c performance share plan psp estimate value psp psp cycle pay estimate value psp cycle pay value year psp cycle mgb stiftung der f hoffmannla roche ag fr mitarbeitergewinnbeteiligung employee profitshare foundation supplement occupational pension benefit include provision footnote payment pension scheme include annual expense allowance remuneration serve chugai board usd chf shareholding nonexecutive member ofthe board ofdirec directors andr hoffmann andreas oeri tor person closely associate member founder family closely member ofthe executive committee associated belong shareholder group son closely associate held share pool voting rightsat end show table group hold share issue sharesandr hoffmann serve spokesman stock optionsstocksettle stock shareholder groupdetaile information appreciation right group find finance report december member corpo note roche group consolidated financial rate executive committee hold option stock statement relate party settle stock appreciation right ssar note financial statement ofroche hold introduce january show ltd additiona december table shareholding december member corporate member board director number share executive committee number share fb humer wm burn b gehrig e hunziker hoffmann ga keller ji bell jkc knowles p brabeckletmathe schwan ljr de vink w frey da julius oeri h teltschik b weder di mauro total total figure include share hold shareholder group pool voting right business report remuneration report stock option ssar number stock option ssar hold member corporate executive committee december ssar issue total number strike price chf expiry date grant value option start ssar chf blackschole value minus ssar option show table issue blackschole formula roche employee stock option option option tradablewith deduction entitle holder purchase roche non average twoyear vest period vote equity security ne strike pricesexpiry date grant value term ofthis multiyear option planthe option ssar show table strike price option show closing number option ssar calculate price roche ne day oftrade prior time issue enter value roche annual medium conferenceall table remuneration ofmember ofthe corpo option show nontradableonethird rate executive committeebstock optionsstock option subject vest period year settle stock appreciation rightson onethird vest period year onethird vest period ofthree yearsunveste option lapse compensation employ ment terminate voluntarily reason retirement vest option exercise limited period timethe fair value ofthe option calculate date ofissue blackschole formula option tradablewith deduction average twoyear vest period ssar show table intro duce roche january place ofstock option ssar entitle holder benefit finan cially increase value ofroche ne grant date exercise date strike price ssar term multiyear plan closing price roche ne day trading roche annual medium conferenceall ssar vest year grant date ieonethird vest end year onethird end yearsand onethird end ofthree yearsvested ssar exercise convert ne seven year grant date unexer cise ssar lapse compensationthe fair value ofthe option calculate date ofissue business report doctor not think d know hep c business report identify early respondershelp motivate patient difficulttocure hepatitis c alain lacroix public relation manager paris public transport system routine screen company doctor reveal hepatitis c virus hcv infectionthe source infection trace gastric biopsy d theyear beforealain recall shocki feel lowhe sayswith sort question mind normally outgoinghe find drawingworrie pass infection toother alain viral genotype difficulttocure b start treatment standard interferon ribavirin april effect month course painful injection week virus october alains hepatologist start himon onceweekly pegasys pegylate interferon alfaacombine copegus ribavirin shetracke effect oftreatment amplicor hcv testafter week virus gonesay alainrecalle elation learn afast response give chance last cureit stay like sinceim extremely grateful researcher find answer thisdisease source infection virtually eliminate revise operative procedure diagnosis therapy monitoring sensitive test need diagnose hepatitis c potentially fatal disease symptom monitor treatment response early responder therapy pegasys copegus enjoy good chance cure reliable measurement viral load today roche offer sensitive realtime pcr monitoring test cobas taqman platform well enable doctor confirm hepatitis c clearance business report create sustainable value management approach business integral society provide roche good position respondour busi essential productsjobs economic bene ness strategy base create fitsthe success ofcompanie largely determined value patient employee shareholder contribute society society focus innovative healthcare solu value create offering need product tion unmet medical need service relevant healthcare management model sectorwhere product active core sustainability people live ensure health beingwe perform essential function society minimumroche run business compli obtain licence operate ance national international lawsa continue business create sustainable voluntary guideline set nongovernman value ofour key stakeholder tal organisationsoften corporate standard requirementsat rochesustainabil responsible prod ity integral ofour daily businessit uct servicesincreasinglystakeholder demand manage astandalone departmentbut manage impact people envi network people represent aspect ronment actively contribute wide society company allow involvement engagement mean step level sustainability priority consider broad range offactor influence goal find table businessover past decade important complex corporate sustainability management model business report create sustainable value management approach manage risk identify relevant sustainability issue arise business model expectation variety risk expose roche pressure ofour key stakeholder prevent achieve goal analyse link issue roche group manage risk identify economic success themevaluating significance decid develop relevant key performance indicator ing action process kpi identify social environmental ethical risk embed kpi exist business process action mitigate risk possible roche group establish risk monitor finding present strong business case sus business unit individually accountable tainabilitywe identify sustainability issue performance risk conduct regular relevant economic success develop risk assessmentsthese fed consolidate afirst draft ofkey performance indicator tomeas annual group risk report discuss ure value company create main corporate executive committee context stakeholder business plan review audit committee genentech chugai manage major value driver ofthe issue identify risk independently develop innovative drug unmet medical need sustainability business strategy retain attract employee business case protect reputation good business ethic set project define roche busi assure future success receive ness case sustainability aim ensure compensation reward innovation sustainability issue fully integrate maintain licence operate business protect current company value stakeholder acceptance create future value project involve large reduce business risk network people represent aspect improve operational efficiency businessfacilitate corporate sustainability committeethe project stage roche business model business case sustainability business report create sustainable value management approach scientific community government ngos employee regulatory authority productivity performancesalary inno liv cat eiv nse e h te ilt nh n ovol atut ei ns operate doctor patient trust reputation income roche return investment investor patient group health benefit capital healthcare payer society supplier business partner continue develop business case engage employee sustainabilitythis include finalise set ofkpis integrate internal reporting end survey internal stake planning targetsetting business pro holder employee effectiveness cesse affiliate aim use internal communication attitude project finding external sustainability companyfurther detail find report stakeholder engagement page work customer engage key stakeholder customer patient benefit stakeholder millions ofpeople medicine diagnosticshealth authority world influence interest roche pay healthcare professional pre include patient medical community scribe administer laboratory employee government regulator non perform diagnostic testingour product sell governmental organisation ngo share country improve patient health holder quality length oflife build maintain relationship communicate patient health group help well understand needs care professional pass patient view develop business strategy generate max productrelate website imum benefit company stake wwwaccuchekcom wwwbonepaincom holdersthe diagram relationships key issuemanagement system patient stakeholdersshow main benefit rela associationsin roche work number tionship different group patient association global regional business report hcraeser cisab slairetam emocni sboj dna emocni relationship key stakeholder income healthcostbenefit taxis job donal tii oce nn sse operatecreate sustainable value management approach national level issue important patient time innovest rate sustainability healthcare policy patient access healthcare dis rank global pharmaceutical company ease awarenesseducation patient information result clearly support integration ofsus maintainclose relationship health author tainability business itie healthcare professional ensure new product meet legal requirement user need partnership supplier pharmaceutical division carry aim supplier service provider extensive stakeholder engagement project meet internal standard employment key opinion leaderspatient groupsoncology soci environmental performance legal etiesclinical trial group research commu requirement roche internal guideline explain nitythe project aim gain global perspective conduct expect company group perception roche purchase basis develop relationship key supplier monitor comply guideline dialogue customer provide positive questionnaire onthespot audits keep negative feedback reality check particularly close eye workplace safetyindustrial important source ofinformation improve hygienepollution waste management product servicesensure successful product launch meeting need ofour customer twothird supplier audit theend ofcompliance find accept increase value shareholder able good ofthemroche work andinvestor remain help improve standard supplier refuse audit aim achieve fair valuation business orrequest improvementroche cease communication base principle business fair disclosurewe communicate investor wide financial community help inform web investment decisionsan increase number investor seek information environ corporate sustainability committee charter goal mentalsocial governance issue activity wwwrochecomsuscharter access medicine wwwrochecomsusaccess engage directly investor patient group wwwrochecomsuspatientgroup annual general meeting customer visit investor relation wwwrochecominvestor roche rocheorganise event annual medium wwwrochecommedia halfyear report investor update supplier wwwrochecomsussupplier participate broker conference hold employee wwwrochecomsusemployee road show key market scientific community wwwrochecomscience andwwwrochecomsusfoundation roche investor relation team rank government ngo regulatory authority health institutional investor good switzer care payer wwwrochecomsusexternalaffair land pharmaceutical sector irmagazine europe judge investment com munity event good continental europe priority action sector key priority table roche list healthcare leader dow ensure maximum contribution sus jones world dow jones stoxx ftsegood tainable development broad sustainability indexesfor yearfor work plan cover everyday activity business report key management topic ethical social issue extend access medicine integral impact business man healthcarealong preventiondiagnosistreat agedthese include ment monitoringworke government organisation way increase valueaccess affordability ofour access innovative lifesaving test medicine diagnostic medicinesthis roche implement dif retain attract talent ferent programme partnership improve business ethic access develop develop country responsible marketing conduct ofclinical trial value innovative product patient safety product quality new technology cancer second big killer europe respect human right heart disease oncology specialist suggest cost innovative drug avastin section explain issue roche treatment colorectal cancer prevent importance roche respond doctor increase preva lence cancer stretch healthcare budget debate continue value access affordability howevera focus price drug ignore medical value product provideroche develop product service save innovative drug avastin herceptin mabthera improve live great contribution roche tarceva xeloda revolutionise way society countless people cancer treat provide significant benefit develop develop world access million ofcancer patient improve effi tests medicine need ciency ofhealthcare systemsthese drug slow progression cancer dramatically improve develop country lack basic quality life save life healthcare facility medicine early stage ofthe disease box need infrastructure health professional toensure right diagnosis right increasingly find government payer medicine right peopleeducation grant reimbursement oncology drug essential combating spread preventable see demonstrable benefit infectionsinclude hivaids patient society healthcare system example base remarkable result early industrialise nation availability breast cancerpayer country take medicine vary neighbour exceptional measure reimburse early treatment countriessome patient disease herceptin drug receive regulatory able live longerhealthi life simply approval live vary level access medicine medicine oftotal healthcare spend medicine availablesome people afford themor diagnostic testsbut use ofdiagnos insurance pay tic combine medicine dramatically increase effectiveness healthcare enable pre vention early diagnosis treatment treatment business report key management topic priority action priority goal progress embed ensure contribute identify businessrelevant sustainability issue analyse link sustainability tosustainable development issue roche economic success daily work begin develop key performance indicator measure progress increase success pilot sustainability risk identification process flag topic business reselecte djsi ftsegood index wwwrochecomsusprinciplesobjective access continue develop new marketing application file marketing approval receive healthcare innovative medicine patient participate clinical trial way increase access people live hivaid cover reduced pricing toour product globally establish technology transfer initiative subsaharan africa indevelope develop andthe ldc agreement sign develop tamiflu manufacturing capacity increase year country wwwrochecomsusaccess ensure strengthen ethical code conduct elearne programme available language responsible compliance awareness andlaunche country business roche activity publish revise position paper clinical trial practice publish detail clinical trial trial result independent website phase patient trial seven different medical condition publish time develop guideline work patient group publish list key group website animal testing site aaalac accredit wwwrochecomsusgovernance wwwrochecomsusresearchdev wwwrochecomsusethics patient safety provide highly effective strengthen safety risk management plan emphasise safe use medicine benefit ofroche product maintain positive benefitrisk profile exceed risk update global website improve transparency disclosure onour minimal adverse drug safety process reaction wwwrochecomsuspatientsafety retain establish programme genentech rank roche pharmaceutical science attracttop talent toretain attract magazine employer biotech pharmaceutical industry good talent right job roche employee survey proud work roche foster performance key management position fill internally culture eligible employee participate employee nonvoting equity security programme introduce new secondment policy enable employee contribute toproject develop country month launch roche engage focus engage employee business strategy wwwrochecomsusemployee safety implement action plan develop position paper cover key issue health atall site achieve long develop allocate sitespecific goal contribute group goal environmental term group goal organise global conference focus risk management protection reduce accident energy efficiency development action plan reach goal absence rate issue group directive energy conservation base international reduce environmental energy workshop include energy efficiency standard equipment impact installation ensure energy efficiency meet fiveyear target reduce emission greenhouse gas target volatile organic compound voc soon plan reduce emission site receive roche responsible care network award greenhouse gas voc outstanding low accident rate positive trend improve compliance receive relevant fine relate roche standard wwwrochecomsusshe business report key management topic need common view nil wilke karolinska institute stock holm sweden discuss research role government industry help cancer patient treatment need key finding research huge difference european country investment cancer treatment time take approve new drug mean access treatment vary widely cancer account total disease burden europe spend ing treatment amount total health care cost pharmaceutical company help government help improve access wide research effectiveness drug cancer treatment market help underline cost pharmaceutical company develop innovative effectiveness company like roche provide drug healthcare system integrate information doctor value new drug drug therapy programme ensure help sure offer patient need patient access authority individual country currently make isolated decision universal evaluation procedure homogeneous reimbursement process provide common view innovative drug present enormous opportunity effectiveness drug help speed treat disease unmet medical need approval process availability market interest healthcare provider pharmaceutical industry patient alike recognise value innovative new drug increase access paneuropean comparison patient access group continue work cancer drug karolinska institute achieve common aim monitoring bring great cost benefit programme include additional health benefit increase respon treatment testing normally sibility demonstrate medical receivedwhere necessary continue provide economic benefit product bring drug free charge product com mercially available enable global access hospital clinic worldwide sell product service compensate patient take roche country customer access trialsthis money fund additional regular channel clinician nursing staffeducational centre research practicespharmacie hospital possiblephase ivor post approval trialsallow clinician familiar provide free medicine testing patient new drug safety profile prior involve extensive phase iiv clinical trial widespread availability business report key management topic united states support patient continue research development new assistance programme provide free medicine hivaids medicine people need inadequate promote educationtraine knowledge health insurance include roche sharing patient assistance programme partnership donate technical expertise local service prescription assistance provider manufacturer genentech access care foundation patent price hivaids medicine genentech endowment cystic fibrosis provide free medicine eligible uninsure million people live underinsured patientsin october genentech disease subsaharan africaimproving access announce double contribution hivaid treatment remain priority independent charity provide financial assis tance medical treatment ofeligible patient roche policy enforce exist patent genentech unveil plan begin apply new patent medicine ofitskind programme cap overall cost develop country ldc avastin usd year eligible sameapplie hivaid medicine sub patient fdaapprove indication saharan african countrieswe supply protease programme available eligible patient inhibitor invirase saquinavir viracept nelfi regardless insure navir noprofit price ldc company anticipate launch new subsaharan africa low price programme quarter medicine viably available long termroche supply drug patient benefit access free roche group reduce price country define world product bank low low middleincome number patient actively participate phase iiv trial worldwide noprofit pricing apply mil number patient benefit lion people country cover patient assistance programme people live hivaid increase united state include reduce price charge total low low middleincome country programme develop country patient cover roche pricing policy hivaid patient live ldc healthcare need people different coun subsaharan africa try community hugely varied hivaids patient live low provide single approach low middleincome country assess need respond appro total priately difference play active role primary role improve discover innovative medicine unmet needswe constantly strive neweffective way implement programme help people live increase access product service poor country hard hit certain include number ofprogrammes expand access disease strategy improve access hivaids treatment develop world medicine develop world example clear patent pricing policy donate product ldc define united nation find build partnership governmentsngo httpwwwunorgspecialrepohrllsldclisthtm commit party business report key management topic share manufacture know country need luc schnitzler technical expert roche technology transfer initiative tti roche technology transfer initiative tti launch january help compa ny manufacture generic version hiv medicine invirase saquinavir develop country subsaharan africa people hivaid live country different company offer voluntary licence select company roche offer free onsite technical assis evaluation criterion use ensure company tance appropriate local manufacturer eligible work produce saquinavir safely countrie patent policy mean license unnec currently comply recommend improve essary believe offer value local com ment reassess future panie knowledge infrastruc ture start production quality medicine meet local standard sup job involve port local manufacturer possible ulti role assess capability interested com mately manufacturer responsible quality panie provide technical knowhow generic medicine eligible company express interest manufacturing saquinavir agreement confident programme suc place south africa kenya cess yes strong interest show important company suffi manufacturing knowhow area hit hard cient capability hivaid highly motivated succeed technology transfer initiative box nose subsaharan africa infant agreement technologyshare reach expose hiv patient month january launch region hivaid treatment monitor discussion continue company country cambodia treatment access programme ctap publicprivate partnership increase amplicareviral load test allow doctor moni availability hivaid therapy provide tor precisely progression patient hiv local training healthcare professional infection modify treatment drug resis launch programme enrol tance control amplicare local patient provide hivaids training authority hospital build equipped cambodian healthcare worker laboratoriestraine lab worker diagnose september open permanent treatment monitor patient diag centre capitalphnom penh business report key management topic care partnership roche implement elearne programme pharmaccess foundation help behaviour business roche principle hivaids treatment sustainable strengthen guidelinescode conduct strengthen local health system train african healthcare awarenessthe programme available lan workersin host fourth care man guagesand rollout complete early agement exchange workshop training meeting target participation rate healthcare worker african coun exclude employee chugai genentech triesthe event provide valuable insight affiliate compli real need people involve fight ance programme hivaid africathe finding submit publication global initiative increase compliance awareness lead high number allege division tropical disease compliance failure refer compliance offi run series workshop audit quality cerout allege compliance failure case assurance researcher manage moni require corrective action include termination tore trial tropical disease ofemployment contractsin continue audit trial ofleishmaniasis support raise awareness code conduct training event subsaharan africa asia emphasis local training initiative web ethic research development access programme partnership ethical concern arise develop new wwwrochecomsusaccessprogramme medicine diagnostic groundbreake sci hivaids patent pricing policy ence stem cell research bring great benefit wwwrochehivcom present risk comes responsibil roche patient assistant foundation itie wwwrocheusacomprogramspatientassistasp roche clear position ethical issue retain attract talent affect researchwe update global posi tion statement clinical research september business strategy base innovation comprehensive document explain employ engage good people key policy include information clinical trial knowledgebase businesspeople work develop countriesprotection genetic datum pharmaceutical industry want employer publication trial web databaseall offer clear strategy innovation chance policy position statement find tomake differencedetail retain website attract talented employee find sec tion peopleon employee inevitably come ethical con cern work clinical trialsifthese resolve team employee business ethic contact global ethic liaison officeifa query satisfactorily resolve process code conduct compliance factfinde consultation peer appro priate subjectmatter expert refer corporate principle describe company internal committee expert want employee proud work stilluncertaintyan independent external advisory partner trust principle com groupthe clinical research ethic advisory group bin directivesguideline policy creag consult specific areasform code ofconduct total query bring global business report key management topic innovative use technology refine reduce animal study research markus von kienlin hansruedi loetscher preclinical imaging department basel explain magnetic resonance imaging mri help strengthen pipeline reduce number animal need mri reduce need animal mri use magnetic field create image body harm animal way mean animal image time change time monitor reduce therapeutic area mri total number animal need addition imag roche wide range animal model cns dis ing datum reliable measuring order use mri identify pattern brain activity animal begin study usually associate disease effect treatment lead improve statistical outcome wealso use mri measure efficacy com pound animal model metabolic disease advantage mri diabetes mri noninvasive monitor physiological pro cesse live unperturbed organism mri use mri roche compet apply human animal allow itive advantage direct comparison finding particularly use feel edge combine ful disorder central nervous system cns advanced mri technology sophisticated ani mri unique tool bridge preclinical mal research particularly cns disorder research animal early clinical development commitment extend mri clinical study human human translational medicine ethic liaison office resolve mous sample ensure patient confidentiality require escalation redesign ofpatient consent form clear key topic address creag meeting include policy transparency clinical responsible animal testing trialsand review recent case bring global ethic liaison office roche take public concern use ani mal scientific research seriously second independent panelthe science ethic support effort find alternative include advisory group seag provide roche external organisation swiss rs foun guidance advice counsel issue broadly dation replacereducerefinein plan relate geneticsgenomic proteomicskey establish roche rs awardto stimulate topic discuss include use ofanony internal effort area business report key management topic use animal result active member major industry associa obtain thembut animal experiment tionsroche contribute review oftheir code suitable way identify practicethese include efpia code ofpractice effect legally requiredwe use promotion medicine review test cause animal distresssuch november revise ifpma code noninvasive magnetic resonance imaging box pharmaceutical marketing practice come force january design animal welfare audit check list contractor goal encourage general manager roche affiliate discussion industry independent responsible ensure compliance auditing possibly involve animal welfare organ national code practicewhich base isation ofcontractors specialised animal ifpma efpia codeand applicable law experimentation company marketing pharmaceutical compliance monitor internal audit team com animal pliance officer research mouse rat nonhuman primate animal research strongly believe patient carry contractor represent active role decision health ofall animal roche group wellbeingto ensure thiswe work alongside patient group share aim provide new expect testing site receive effective safe treatment quickly system accreditation association assess atically possible ment accreditation oflaboratory animal care aaalac end introduce set ofguideline work patient group february aim cre web eat genuine mutually beneficial partnership reflect common value integrity indepen roche corporate principle code conduct dencerespect transparencythey specify wwwrochecomsusprinciplescodeconduct work carry benefit patient repre clinical research ethic advisory group sente groupand group wwwrochecomsuscreag ask endorse specific product box science ethic advisory group wwwrochecomsusseag protect intellectual property animal welfare wwwrochecomsusanimalwelfare adequate protection innovation essential policy position paper industry ifwe continue find new diag wwwrochecomsuspoliciespositionsguideline nostic drug fight disease cancer alzheimersdiabete hivaid responsible marketing pharmaceutical company patent new drug sure recoup investmentby patient right factual information sole manufacturer ofa drug limited medicineswe follow external guideline code period usually year company practice marketing pharmaceutical motivate ensure process innovation include world health organization ethical interrupted continue bring new criterion medicinal drug promotion improve medicine market internal guideline design use promotional material activity comply file patent world develop regulation concern advertising directly countriesto ensure patient prevent consumer receive roche medicine patent business report key management topic work effectively patient group jean mossman ceo lead uk cancer support charity cancerbackup help roche develop guideline work patient group ensure patient opinion take account company patient group well work patient want access effective treatment industry want commercialise product com mon agenda right treatment right patient right time patient group company well achieve effective partnership side equal compa byunderstande perspective longterm ny contribution valuable partnership provide mutual benefit patient group try influence group agenda try benefit company patient brand patient group product company society general ensure relationship not suffer patient not medicine direct mak change personnel ing treatment ineffective input patient ensure information drug simple clear com codevelop guideline working panie well understand experience patient group roche living disease matter patient roche recognise team work drug fit treatment patient group different way common plan approach need ask draft guide line roche ensure use company avoid work employee reflect need patient patient group patient organisation counterfeit pose health risk ment custom official utmost tackle problem statement fake pharmaceutical diagnostic product counterfeit available website infringement intellectual property rightsbut importantly endanger life biosimilar wellbee patient fake cause illness death ifthey contain harmful ingredient innovative biological medicine reach deprive patient ofproper treatment end oftheir patent period year introduction product claim responsibility prevent control drug similar original likelythese know counterfeiting rest primarily national gov biosimilars followon biologics manu ernment international organisation roche facture ofboth active substance finish cooperate worldwide regulatorslaw enforce product require high level quality control business report key management topic ensure clinical safety approval biosimilar concern clinical trial develop require set guidelinesand con country carry stan tribute development dard develop world roche employ ich gcp minimum global standard web roche trial introduce additional policy conduct clinical trial low marketing guideline middleincome country support wider wwwrochecomsusmarkete global position clinical research guideline work patient group wwwrochecomsuspatientgroup support train good clinical practice sub global patent function wwwrochecomsuspatent saharan africa quality assessment asia counterfeit wwwrochecomsuspatent forum ethical review committee biosimilar wwwrochecomsusbiosimilar asia western pacific region fercap roche clinical trial protocol registry conduct clinical trial trial result database medicine release evidence publish data clinical trial safety effectiveness provide people benefit finding welldesigne control clinical study online clinical trial protocol registry result database address provide information clinical study roche conduct com new trial key result complete pliance international guideline phase iiiv trialsboth registry andthe database approve regulatory authority include host independent company food drug administration fda european agency evaluation medicinal detail clinical trial trial result product emea ethic committee local publish website launch institutional review board april people access databasethis include study board ensure propose trial acceptable breast cancer anemia hepatitis participant fully inform benefit addition december roche trial risk relate participation post national institute investigator appropriate action protect health global registry wwwclinicaltrialsgov patient harm follow request patient group recom framework discuss resolve eth mendation whoand consultation ical issue clinical research clinical research ethic advisory group creag good clinical practice toolkit provide post information phase trial con involve ensure trial pharmaceutical ducte patient post year datein seven product meet international conference har different medical conditionsthis enable patient monisation ich internation disease seize albeit small allyrecognise standard good clinical practice opportunity find new treatment solution local law web guideline available intranet employee work trial train global position statement clinical research require follow themall trialsand process resolve ethical issue clinical trial system conduct themare audit develop country pharmaceutical division quality assurance wwwrochecomsusclinicalresearch team clinical trial registry wwwrochetrialscom business report key management topic ensure patient safety firm safety effectiveness product product quality marketplace give early indication potential product issue help user medicine diagnostic preventative action right expect effort ensure safety roche systematic process collect early plan update website ingreporte analyse datum ensure patient include detail patient safety product safety product lifecyclein com quality relate procedure pliance local regulation web work hard protect patient potential adverse reaction drug examine patient safety report adverse event identify related wwwrochecomsuspatientsafety product incidental useof risk management procedure productadverse reaction identify early wwwrochecomsusriskmanagement possible classified term severity risk outweigh benefit position new technology drug safety department work roche affiliate monitor drug new technology offer great opportunity launch report suspect medical advance development use adverse reaction roche mandatory create legitimate social concern phase iiii trialsonce drug launch reason continuously monitor evaluate rely patient healthcare professional discuss use ofdeveloping technology authority soemployee immediately report information suspect adverse biotechnology use living organism event quality issue drug safety depart modify product process specific use ment application biotechnology include genetic engineeringgene stem cell therapyroche risk management procedure ensure patient currently carry stem cell research relevant authority inform promptly adverse reaction confirmedmany biotechnology potential replace health authority require report certain chemical drug manufacture adverse reaction daysour country make process safe environmentally manufacture site subject health soundin publish new position paper authority inspections safety health environmental aspect biotechnology paper nanotechnology pharma manufacturing standard lie rule currently draft tightlycontrolled procedure ensure high quality standard compliance external web regulationsthey cover aspect business include comprehensive safety datum review roche position paper biotechnology process ensure new information wwwrochecomsusbiotechnology receive drug assess product infor roche charter genetic mation update necessary wwwrochecomsusgenetic science ethic advisory group diagnostic division ensure product design wwwrochecomsusseag production release postmarket surveillance embryonic stem cell therapeutic cloning activity meet regulatory customer require wwwrochecomsusstemcell mentsour global complaint handle system con bioprospecte biodiversity wwwrochecomsusbiodiversity business report key management topic unlock breakthrough potential avastin peter wenner franchise director avastin roche revolutionary cancer treatment avastin launch successful avastin significant advance cancer treatment antiangiogenic agent con sistently improve chance survival metastatic colorectal lung breast renal cell cancer limited effect authority recognise consider able benefit avastin bring patient grant reimbursement drug record time use colorectal cancer treatment launch february approve gramme unlock potential drug country patient recruit trial people expect trial lifecycle drug avastin develop different type ofcancer parallel not unusual roche unique lifecycle management struc normally drug show work effectively ture contribute success product indication develop roche absolutely lifecycle team include individual genentech take bold step conduct trial fromevery key function organisation research avastin pancreatic prostate ovarian cancer development manufacture regulatory marketing atthe time continue trial colorectal lung dedicate product goal unlock breast renal cell cancer result avastin potential product benefit patient approve short timeframe metastatic maximise value brand colorectal cancer wait approval use metastatic breast lung cancer lifecycle management structure close cooper ation roche genentech contribute addition phase iii trial currently avastin enjoy fast launch underway extensive development pro oncology product date respect human right web roche believe firmly universal human respect human right right declare united nationsour group wwwrochecomsushumanright employment policy prohibit discrimination group employment policy harassment force child labour wwwrochecomsusemploymentpolicy ground respect employeesright join legally recognise employee association fur ther information commitment human right website business report ve get life child get father business report neweffective treatment option people withrheumatoid arthritis steve robsonfrom bedford ukwas hefound rheumatoid arthritis ra onassignment companya specialist piping contractorhe suddenly develop severe pain hishand work jackhammer day worsen pain swell hand foot shoulder soon everyday task like tie shoelace difficult impossibleeven walking unbearableno long able hard physical worksteve fortunate employer offer transfer office job year diagnosissteve need hip replacementbecause disease destroy jointfor year try variety treatment work longin rheuma tologist enrol clinical trial mabthera rituximab course mabthera year agoand subsequent coursessteve pain free joint swell reducedhe walk comfortablydo household choreswork thegardenand play football child understandable describe discover mabthera like win lottery saysi not swap win lottery therapy selectively target b cell play key role ra mabthera interrupt series reaction process lead joint inflammation cartilage loss bone erosion characteristic disease patient ra treat mabthera clinical trial date mabthera market genentech biogen idec brand rituxan business report people brief employment policy set commitment employee expectation ofthemit new job create line objective practice aspect million swiss francsremuneration pay people management include talent attraction genentech rank roche pharmaceu recruitment performance management develop tical science magazine employer ment compensation diversity discrimination biotech pharmaceutical industry zero tolerance child labour freedom asso national employer ofchoice ciation health safety environmental award protection ofemployee survey proud work roche total employee fulltime equivalent fte regret loss employee participate roche con number employee nect nonvoting equity security programme hour oftraine employee employ people country employee fte operate divisional group world roche create new job increase total workforce roche pharmaceutical chugai roche business strategy base sustained genentech innovation growthour main source ofinnova tion come talented individual companytherefore ability retainattract recruit talented motivated employee isvital continued business successto retain diagnostic peopleit essential successfully develop skill career rochewe continue attract recruit good talent market enable business grow employee fte region want attractive employer europe staff potential recruit stage latin america attraction recruitment performancedevel north america opment retention value chain corporate principleswe state commit ment create work environment pro mote mutual respect trust integrity asia employee treat fairly value chain attraction recruiting performance development retention business report people roche engage strategy base executive development roche engage support strategy provide great insight build maintain culture innovation ursula redeker global head safety technical science strategy clearly set direction com panythe entire roche community connect androche engage facilitate roy rothenberg finance manager korea deliver sustained growth value motivat ing inspire coworker roche engage change leadership model leader time paul nakagaki head research strategy talent attraction recruitment want attract good talent industry door rocheprogramme launch achieve objective remain enable prospective employee search employer choice monitor perception job company website roche employer feedback functiondivision countryjob seeker receive website rating external survey personalise email alert appropriate posi tion available accumulate continual effort employer choice global talent pool ofmore external recognise external study didate process allow build world science magazine vote genen relationship potential recruitssince tech roche pharmaceutical fill position system company employer biotech pharmaceutical industriesthe survey cover roche keen reach people pos question corporate image leadership sible potential employer october direction work culture environment social launch accessibility feature career responsibility compensation benefit website improve usability accessibility worklife balance consistently improve people disability position yearsgenentech hold number spot fifth year run erecruite halve time take recruit improve efficiency reduce dropout roche name employer rate desirable candidate enable act choiceby survey canadachileitalygermany fast competitor help increase portugalspain usour australian recruit mobility development opportunity exist ing team award good recruiting team e employee chance work roche diagnostic germany name well roche groupby open employer woman list awards internal job market receive local division visit dedicated career website httpcareersrochecom business report people develop talent international assignment monica arosio head international assign ment roche explain roche encourage employee towork abroad develop ment company roche offer international assign ment roche longstanding tradition promote sustain international assignment programme business need individual train deal successfully complex itie different market country culture international assignment con skill everchange environment like tribute individual company performance enable people reach limit strive international assignment offer unique oppor achieve international assignment tunity expose unusual circumstance powerful tool develop talent share good practice personally professionally culturally foster country come innovative way great creativity flexibility adaptability crucial support strategy performance management ment score area remain development global employee research company isr average pharmaceutical sector high success business future performance company norm roche depend motivated employee work cul pharmaceutical roll new global ture emphasise individual responsibility formance management process division focus training feedback employee receive regular feedback performance meet manager individual site division discuss career performance management training policy meet local need example programme place affiliate pharma global informatic roll career cover total workforce development programme employee similar previous year training totalroche venezuela celebrate development plan agree graduation ofstudent threeyear train employee ing course senior sale representative pharmaceutical division conduct global addition offer development opportunity survey performance management end exist employee young people threequarter employee opportunity train apprentice survey rate development planning prospect career rochewe currently train positively performance monitor training apprentice feedback identify key area improve business report people develop successful career like fact roche expect efficiency result employee provide fair care work environment udo bckert head technical services basel company year provide need good job work close contact talented colleague world fun enrich experience evamaria gutknecht female chemist hire industry roche year global opportunity enjoy inher year roche louisa shen work career roche tremendously broaden arange diagnostic role switzerland canada perspective work personal life work china demand challenging forcertain boring day mid toplevel manager asia roche pharmaceutical introduce new policy pacific diagnostic division take enable employee expand horizon annual apac discovery programme september contribute skill expertise project twoweek course internationally develop country take secondment recognise nanyang business school singapore month away regular job focus development leadership skill participant select high leadership roche diagnostic set exchange pro potentialconsistent track record commitment gramme enable employee department companygraduate programme germany switzerland work form pool emerge leader ensure roche country continue success regionrapid growth asiapacific company underline need focus develop leadership skill build highlytrained ambitious workforce pool oftalente leader roche ensure region future successin launch roche engage new senior executive development programme career roche internationalwe manager group keen enable employee broaden programme focus help senior leader experience working country box apply leadership skill engage employee employee different country strategy enable deliver currently international assignment business goal country business report people leadership charter set consistent frame engage employee work ofleadership competency essential man ager company focus provide engage regularly employee assess model ofintegritydrive business successmeete satisfaction level gain feedback pro need ofour customersand motivating employ gramme late survey employee ee help improve performance effectiveness internal communication attitude companyaround senior middle manager group employee take response rate set specific goal overall objective raise value company perform ance measure ability meet ofthose survey say proud goal contribute increase operating work roche comfortable present profit tax capital charge opac roche positive light outside worldfac tor cite roche stand succession planning review company include group strategy princi potential candidate senior management posi plesit success innovation product tion approximately business good working atmosphere motivated manager yearwe find average succession coworker appreciation employee candidate position compare social benefit previous yearthis target range ofto candidate position global intranet internal newsletters letter corporate executive committee training information meeting employee inform company objective strategy result total hour invest current research new product addition train employee division site communication development million channel employee train time day day day employee hour hour hour pay benefit retention roche commit provide fair compensation benefitsbase local competitive condition addition personal development opportu employee contribution business nitieswe consider employee satisfaction work total remuneration cost million life balance vital retain good employee swiss franc total attrition rate permanent staff offer nonvoting equity securitiesown proportion regret loss ship programme employee opportu initiate roche nity financial stake company suc employeeswe areplease research func cessroche longtermlaunche provide tion source innovation continue consistent approach performancerelate equity low number departure qualify base remuneration enable senior manager employee share company longterm financial growth staff turnover regret loss roche connect allow employee usdue legal restriction purchase non fluctuation voting equity company discount rate regret loss employee eligible participate programme business report people promote diversity freedom association diversity workforce invaluable roche respect right employee capacity innovationon success ofour ofan employee organisationroche working business dependsroche tolerate discrim open dialogue legal employee represen ination ground promote people tation country operate roche criterion performance potential record individual membership ofunion functional geographic mobility estimate employee member union employee repre employ people world sente works council similar organisation employee corporate headquarters roche found roche euroforum repre basel region foreigner represent nation send employees europe approximately alitiesaround affiliate company people head national ofwhere company base year management web team include consistently high proportion local staff door roche erecruitment facility httpcareersrochecom want roche attractive employer corporate principle man womenwomen account wwwrochecomsusprinciplescodeconduct total workforce centrally group employment policy track manager senior manager wwwrochecomsusemploymentpolicy weare work attract retain woman human right wwwrochecomsushumanright proportion woman roche local employer choice award steadily increase wwwrochecomsusempofchoice httpcareersrochecom gender diversity safety health environment wwwrochecomsusshe woman total workforce woman management number woman management position woman candidate management position recognise healthy worklife balance vital wellbeing performance ofour employee offer range programme enable employee balance work family com mitmentsemployee choose working pattern suit fulltime parttime flexi time work homewe offer option parttime employment requirements job permitaround employee work parttimeparental leave sabbatical arrange worklife balance parttime employee business report communitie community involvement describe support project promote new group policy donation noncommer advance basic science encourage young cial sponsorship target key area people enthusiastic life science improve access medicine diagnostic addition local projectswe provide global sup promote advance basic science port research specific area number education foundation roche organ tran encourage innovation excellence plantation research foundation roche contemporary culture arts foundation anemia research rofarto date support community employee rofar award seven million swiss franc live work research project world roche research foundation switzerland give civic responsibility financial support research project young provide environment inspire employee scientist mba fellowship pro roche successfulsustainable business gramme provide grant encourage talented scientist complement medical science usually involve project qualification degree business knowledge expertise significant dif ference prefer work closely local partner party special expertisewe measure encourage innovation art success impact project total spend close link artistic creativity publish detailed figure spend innovation activity science community supportwe donate drug businessroche patron disaster reliefand pandemic situation contemporary art music centuryas commitment roche com community support area spend mission sponsor new musical work outstand humanitarian social project e contemporary composer box science education art culture november roche launch joint project community environment salzburg festivalthe roche continent youth art science series encourage young people attend contemporary music event access healthcare explore link innovation music art innovation science use expertise improve access health care medicineswe focus effort roche found maintain museum benefit great needfor tinguely ag baselshowcase innovative art detail workrochenjazzlaunche september monthly evening live contemporary jazz music hold museum tinguely regularly promote advance science attend employee member public plan roll local country roche drive force rochenjazz event roche site scientific community activity world business report community connect innovation music science cleveland orchestra partner roche commission pioneer international project advancement contemporary classical music conductor franz welsermst dis cuss make partnership work innovation important cleveland orchestra cleveland orchestra stand innovation tradition tradition mean hand thing carry forward involve movement not exclude innovation link innovation music think roche commission successful science absolutely share common goal aim science music discover quality work quantity like roche exist form find cleveland orchestra know outstanding science take technical approach research technical ability innovation new piece musician emotional approach s music chance hear time quality fascinating point meet performance high level organisation develop new medicine compose new share curiosity future recognise music work create response physical need invest emotional human being support community found independent charity roche employee action charity trust react support community guide help coordinate employee donation employee focus primarily local project community supportit goal provide support identify themwe encourage employee play select sustainable project charitable community volunteer organisation address longterm humanitarian fundraisingroche match fund need postdisaster rebuildingespecially raisedouble total contribution develop country roche begin work unicef web support school malawi attend child orphan hivaid fund pro group policy donation criterion ject come annual global roche sponsorship wwwrochecomsusgive employee aid walksome employee roche drug donation policy site country take december wwwrochecomsusaccess roche match fund raise roche foundation donate total million swiss franc wwwrochecomsusfoundation orphans malawi rochenjazz wwwrochenjazznet business report monitor blood glucose day hospital month business report monitoring diabetes avoid complication ceo eschenbach optik japantomio koga demand job busy scheduleeven sohe manage combine private role asa highschool baseball umpirein private life tomio shoulder anotherquite different responsibilitywhen doctor diagnose diabetes routine checkup year agohe deeply shock conscientiously embark histherapynever miss appointment hospitalhoweverif manage welldiabete cause discomfort symptom tomio gradually forget illness point stop see doctor altogether turn point come trip germany colleague tell himwhen dia betesyou monitor blood glucose level regularlyor risk develop cardiovascular complicationswhen explain hard itwa combine frequent checkup schedulehe tell check blood glucose myselfsay tomiohe check blood glucose level regularly accuchek compact plus manage data accuchek smart pix mean track reading quickly identify deviation apart fast need bloodmy new meter small easy use particularly important business travel monitor people type diabete produce insulin body not produce effective use diagnosis control blood glucose level adopt healthy lifestyle diet inject insulin tablet product accuchek meter strip enable people diabetes monitor blood glucose accurately conveniently business report safety health environmental protection brief improvement site imple mentation necessary action monitor publish new position paper key enforce strategically important supplier issue base riskassessment level spend reduction roche accident rate audit monitor management energy use employee reduce performance supplier audit reduction greenhouse gas emission recommendation improvement inorganic emission air reduce implement safetyhealth environmental protection roche commit uphold high environ separate business success mental safety standard set responsible care fully integrate global initiative establish chemical employee expect play pro industry achieve continual improvement tecting environment make roche safe performanceour responsible care network healthy place work communicate commitment standard provide forum site share advice commitment enshrine roche good practice corporate principleswe revise safetyhealth environmental protection policy late management system cover relevant restate strengthen commitment aspect internationallyrecognise standard international organization stan invest million swiss franc dardization environmental management stan infrastructure new manufacturing building dard iso european ecomanage extension exist installation operate ment audit scheme emasit goal cost include service personnel cost achieve iso emas certification amount million swiss franc site roche manufacturing site choose implement standard voluntarily certify iso ofthese site management attain emas certification responsibility implement policy awareness continual reduction risk guideline lie general manager essential prevent accident incident affiliate company individual site manager affect peoplethe environment busi support safety environmental ness risk register evaluate officer site coordinate cor webbase tool information assess porate team divisional champion eco group level build global risk profile delegate responsible raise awareness divisionsin addition regular jobsa total employee work goal fulltime group set number ofnew longterm quanti roche monitor implementation ofthe policy tative target global performance add guideline directive audit site exist goal group audit higherrisk reduce roche accident rate site audit oftenrecommendations baseline workdays lostemployee business report safety health environmental protection reduce general absence rate include illness informative accident anonymously home accident publish intranet site baseline day lostemployee aware potential hazard reduce total energy consumption action prevent similar incident baseline gjemployee improve total ecobalance annual roche responsible care network baseline pointsemployee award recognise sustained outstanding health reduce greenhouse gas emission safety performance individual site base baseline co equivalentunit sale roche accident rate previous reduce voc emission yearsin site receive award baseline tonne vocunit sale stand low accident rate positive trend relevant sherelate fine recognise employee wellbee affect work hourswe start collect occupational health safety datum general absence non workrelate accident assess cause absence safe healthy workplace essential seek possible improvement employeeswellbee productivityin large research manufacturing operationssafety roche offer range ofprogramme site health committee establish help promote employee health wellbee inside safetyhealth environment officer seo raise outside workplace include free awareness organise training implement tech medical checkup workplace ergonomic evalua nical improvement reduce risk work tionscounsellingfitness centreshealthy meal placein small site responsibility lie solely staffrestaurant programme promote seoin total hour healthy lifestyleswe initiative invest globally train roche promote wellbee improve employee worklife balance measure safety health performance roche accident rate number working day lose occupational accident environmental footprint peremployee yearthe rate decrease development roche roche commit environmental protection accident rate rar show positive trend lifecycle product iea decrease number accidentsthe severity research production packaging transport accidentshoweveris go oppo distributionuse disposal site direction ie lose day accident report year concern occupational measure global environmental footprint diseasesboth number recognise case ecoefficiency rate eer ratio lose day case low sale environmental impact expenditure majority case refer ecoefficiency describe world business locomotor system council sustainable development wbcsd concept create value nega health safety tive impact eer take account wide range offactor energy use emission roche accident rate air water weight accord signifi occupational accident cance produce single value high occupational illness eerthe great degree ofecoefficiencya workrelate fatality explanation eer calculate workrelate accident find website million work hour business report safety health environmental protection eer increase ofmore nate soil water aspect biotechnology previous yearthe different source andprevention ofmisuse ofbiological material ofthis tremendous improvement biowarfarethese available website reduction environmental damage par ticular emission air waterinclude correction offormer overreporting energy climate change please development ofthe sale figure global warming climate change ecoefficiency rate document greenhouse gas emission carbon dioxide result human activity sale million chf consider responsible accelerate environmental expenditure global trendsindustry source ofthese emis millions chf sion appropriate measure reduce environmental damage impact international agreement million environmental kyoto protocoland national legislation define tar damage unit get schedule reduce emission eer roche support target set kyoto pro calculate ecobalance define tocol reduce global greenhouse gas emission ecological impact roche operation work goal set consider economic parametersaccording reduce emission year method set swiss agency envi close link car ronment bafu ecobalance take account bon dioxide emission energy usemost mea output environment emission waste ure reduce energy consumption decrease use resource raw material emissionsroche promote measure energyeach parameter weight accord move emissionintensive energy source significance impactby set global target apply innovative building technology con improve ecobalance encompass tinually upgrade infrastructure improve entire environmental footprint individual site energy efficiencyin roche tera able identify focus area joule ofenergyalmost significant improvementsour eco despite business growth balance match global target run ecompetition roche introduce fuelefficient lowemission year encourage employee think hybrid vehicle fleet corporate car environment submit idea reduce emission transport protection initiative benefit hybrid vehicle introduce roche environment cut cost significantly pharmaceutical fleet usa similar example introduce measure reduce programme introduce roche energy use airconditione system group member chugai japan add site entry submit current hybrid car fleet bring total competition launch october employees australia offer hybrid roche responsible care network award vehicle company car roche australia reward energysave initiative encourage site begin offset carbon emission transport help meet global commitment reduce planting tree area destroy fire energy use publish new global position paper set strategy affiliate north south america hold key environmental issuesmeeting year annual energy conservation summit goal hold public position key topic discuss strategy share good practice public interesttopic cover aregreenhouse gas energy conservation promote message climate changeenergylandfill contami employee help conserve energy business report safety health environmental protection roche commit phase halogenate energy use type hydrocarbon potent greenhouse gas ozone depleter cool system reduce holding ofthese gas natural gas tonne compare gas oil hold seal cool system fire extinguish coal er leakage occurresulting emis waste sion tonne tonne renewable energy previous year develop plan replace cool equip district heating ment contain halogenated hydrocarbon fuel business roche diagnostic example company vehicle invest million swiss franc fuel business air travel ammoniabase refrigeration plant head grid electricity quarter indianapolisthe new plant completion replace current cool ing system site contain environmentally hazardous refrigerant emission air measure greenhouse gas emission volatile organic compound voc manu accordance greenhouse gas protocol facturing process particulate combus take account direct emission tion plant contribute local air pollution waste incineration transport power generation smogin roche emit tonne ofvoc fossil fuel indirect emission grid tonne particulatescompare electricity emission halogenate hydro tonne tonne respectively carbon include co equivalent roche emit million tonne co equivalent significant reduction large extent million tonne overreporte main contributor previous year correct introduce closed system suitable exhaust roche calculate impact climate change air treatment number site reduce normalising total emission express co emission equivalent million swiss franc sale result decrease nitrogen oxides sulphur dioxide x previous year emission contribute acid rainroche emit ted tonne tonne x total energy use terajoule burn fossil fuel represent low level reduction overall inorganic total energy use emission previous year total energy use million chf sale invest million swiss francs mod ernise convert power station supply greenhouse gas emission tonne co equivalents mannheim site germany coal natu ral gas reduce emission ofnitro total emission gen oxide nearly year emission total emission sulphur dioxide dust zerothe million chf sale efficient modernise plant cut carbon dioxide emission tonne year reduction ofmore business report safety health environmental protection training manuel glauser head corporate safety environment audit team andreas riesen health protection manager basel kaiseraugst site switzerland talk training roche training group level help embed knowledge group drive awareness company teach teacher hold conference year train seo world share knowledge employee site training raise awareness roche representative use site offer goal education programme issue goal key focus year confer interested knowing ence germany participant create local action plan site support global new recruit introduce procedure goal induction new employee introduce local training general induction depart network seo backbone ment right complete computer organisation roche lead organisation base training programme mandatory site company level provide professional new employee new employee ask knowledge tool support range complete checklist help supervisor tailormade training course classroom colleague help learn procedure base lecture handson train local specific workplace waste tinually work improve yield addition explore possibility recycle valorisation chemical waste result pharmaceutical pro find customer use waste product duction pose potential risk environ process raw material ment dispose responsibly tonne chemical waste generate operation generate tonne ofgeneral incinerate waste compare tonne inert material incineration ash slag previous year increase mainly result go landfillthis increase chemical waste construction waste incinerate primarily rest send landfilllandfill result increase production waste tamiflu historically chemical waste manufacture inert material subject increase monitor roche assume responsibility chemical waste originates manufacturing landfill sitewe conduct risk assessment poten processesto reduce type wastewe con tial leakage preventative actionremedia business report safety health environmental protection tion complete site potentially damage ecosystemsin kilo ongoing gram heavy metal emit treat mentdown previous year additional tonne material paper cardboard glass metal wood plastic roche support research source impact recycle trace chemical include pharmaceutical watercourse environmental risk assessment show active pharmaceutical ingredient water find watercourse primarily cause normal use inappropriate disposal availability clean water critical roche ourproduct consumersnot pollution manufacture pharmaceutical diag manufacturing site nostic product itthe use biotechnol ogy replace chemical process research productionreduce safety risksbut compliance incident technique require great water use million cubic metre water commit fully comply rele commit reduce water consump vant law regulation country tion local programme site level operateour global standard guide effort improve ecobalance line precedence exceed local regu lationsroche receive significant sherelated win idea ecompetition fine incident accident realise roche jacarepagu brazil significant impact people environment cut total water use reuse wastewater report roche group cooling systemsave approximately swiss franc year roche recognise substance themanufacture ofpharmaceutical product water consumption million cubic metre potentially misuse narcotic toxin chemical weapon regulate chemical water use roche small quantitiesunder rig total water use cubic metre orous control compliance applicable million chf sale legislation contaminate wastewater manufacturing web necessaryprocesse onsite pretreatment plant release public treatment policy guideline organisational structure plant watercoursessome volatile solvent wwwrochecomsusshe remove treatmentin tonne position paper organic material total organic carbon toc wwwrochecomsusshepoliciesposition discharge watercourse treatment policy regulate chemical decrease significant wwwrochecomsuschemical reduction partly detection responsible care report major contributor previous wwwrochecomsusresponsiblecare year addition clarecastle site ireland performance datum longterm trend definition considerable improvement toc wwwrochecomsussheperformance elimination process small amount ofheavy metal copperzinc chromium leach pipe acidic wastewater biodegradable business report assurance assurance independent assurance report roche nal guideline definition procedure estab group sustainability report lishe prepare report sustainability performance roche corporate sustainability committee roche group responsible subject perform evidencegathering procedure matter evaluation criterion provide assurance sustainability report e roche consolidated subsidiary responsibility provide conclusion exclude chugai genentech groupall subject matter base evidencegathering year end december procedure accordance international standard assurance engagement isae perform evidencegathere proce assurance engagement audits dure jointly refer subject review historical information approve matter december international auditing assurance standard board iaasb key figure table page plan perform evidencegathere select social dimension information procedure obtain basis conclusion social datum accordance isae limited reason management reporting process able assurance engagementwe perform preparation ofthe report figure audit accord international standard audit accordingly express evaluate subject matter audit opinion follow criterion evaluation criterion describe page evidencegathere procedure include follow work roche group internal sustainability report ing guideline respect responsible site levelassesse roche staff apply care healthsafety environmental reporting group internal sustainability report guideline publish european chemical guideline observe compliance industry council cefic sustainability group internal sustainability reporting report guideline publish guideline visit sample site global reporting initiative gri switzerlandswedenpolandand uscover procedure datum ing pharmaceutical diagnostic divi social datum preparedcollate aggregated sion internally perform test sample basis ofthe internal control environment accuracy sustainability reporting system collect completeness datum social datum social datum group site data perform specific procedure check sample basisthe data social data accuracy completeness sustainability interview responsible stafffor datum collec datum subject inherent limitation give tion sustainability report site nature method determiningcalculate visit group level estimate dataour assurance report assess datum consolidation process read connection roche inter group level business report assurance read perform test relevant dimension information material respect documentation sample basis include base evaluation criterion group policy management report structure documentation system base work describe reportnothe collectanalyse aggregate report datum come attention cause believe social datum social dimension information dis perform test sample basis evidence close sustainability reporting support select datum social datum fair picture social perform regard report datum aggregation ance procedure select site group level datum social dimension information pre pare collate aggregate base perform site visit establish accept measurement analyt chugai genentech ical methodsin material respectsbase evaluation criterion opinion pricewaterhousecooper agbasel roche group internal sustainability report january guideline apply properly select site internal reporting system group level collect datum function design social dimension reporting provide appropriate basis disclosure social dr thomas scheiwiller jrg hutter global reporting initiative report prepare accordance sustainability report guideline gri guideline represent balanced reasonable presentation organisation report accordance global economicenvironmentaland social performance report initiative gri guideline annual report websitethe gri review report confirm meet accordance criterion detail ofhow report indicator find wwwrochecomsusgri franz bhumer business report sale manufacturing overview switzerland croatia argentina czech republic australia denmark austria dominican republic belgium ecuador bermuda el salvador brazil estonia bulgaria finland canada france chile germany china greece colombia guatemala costa rica honduras business report roche global market presence roche global market presence research development service finance toll manufacture party hungary new zealand slovakia india nicaragua slovenia indonesia norway south africa ireland pakistan south korea italy panama spain japan peru sweden latvia philippine taiwan lithuania poland thailand luxembourg portugal turkey malaysia romania united kingdom mexico russia united states morocco serbia uruguay netherlands singapore venezuela business report publish cautionary statement forward fhoffmannla roche ltd look statement baselswitzerland annual report contain certain forwardlook tel ing statement forwardlooke statement fax identify word believe expect anticipate project intend media office seek estimate future similar expression corporate communication discussion thing strategy baselswitzerland goal plan intention factor tel cause actual result differ materially future fax reflect forwardlooke statement contain annual report investor relation pricing product initiative competitor baselswitzerland legislative regulatory development tel economic condition delay inability fax obtain regulatory approval bring prod uct market fluctuation currency world wide web exchange rate general financial market condi httpwwwrochecom tion uncertaintie discovery develop ment marketing new product new use corporate sustainability committee exist product include limitation pierre jaccoudchair negative result ofclinical trial research project tel unexpected effect pipeline market emailpierrejaccoudrochecom product increase government pricing pre sure interruption production loss order publication orinability obtain adequate protection intel tel lectual property right litigation loss fax key executive employeesand adverse emailbaselwebmasterrochecom publicity news coverage statement earning share growth profit forecast inter prete mean roche earning earning share subsequent period necessarily match exceed historical publish earning earning share ofroche annual general meeting march trademark mention enjoy legal protection roche annual report publish german english print nonchloride bleach paper roche annual report issue f hoffmannla roche ltd basel corporate communication business report